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1.1	  Metabolism	  
Metabolism is the set of life-sustaining chemical transformations within the cells of 
living organisms. These enzyme-catalyzed reactions allow organisms to grow and 
reproduce, maintain their structures, and respond to their environments. Metabolism is 
usually divided into two categories; anabolism and catabolism. Anabolism is the set 
of constructive metabolic processes where the energy released by catabolism is used 
to synthesize complex molecules. Anabolism involves three basic stages. Firstly, the 
production of precursors such as amino acids, monosaccharaides, isoprenoids and 
nucleotides; secondly, their activation into reactive forms using energy from 
adenosine triphosphate (ATP); and thirdly, the assembly of these precursors into 
complex molecules such as proteins, polysaccharides, lipids and nucleic acids. 
Catabolism is the set of metabolic processes that break down large molecules. These 
include breaking down and oxidizing food molecules. The most common set of 
catabolic reactions in animals can be separated into three main stages. In the first, 
large organic molecules such as proteins, polysaccharides or lipids are digested into 
their smaller components outside cells. Next, these smaller molecules are taken up by 
cells and converted to yet smaller molecules, usually acetyl coenzyme A (acetyl-
CoA), which releases some energy. Finally, the acetyl group on the CoA enters in the 
citric acid cycle producing water, carbon dioxide and reducing the coenzyme 
nicotinamide adenine dinucleotide (NAD+) and flavin adenine dinucleotide (FAD) 
into NADH and FADH2. These coenzymes transfer their electrons to the electron 
transport chain, which coupled with the oxidative phosphorylation produce water and 
ATP.  	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1.2	  Energetic	  metabolism	  
Glycolysis is the metabolic pathway that converts glucose into pyruvate; it occurs in 
the cytosol of the cell. The free energy released in this process is used to form the 
high-energy compounds ATP and NADH. The net yield of the glycolysis for one 
glucose molecule is two pyruvate molecules, two ATP, two NADH, two H2O and two 
H+. Glycolysis is a determined sequence of ten enzyme-catalyzed reactions. The 
intermediates provide entry points to glycolysis. For example, most 
monosaccharaides, such as fructose and galactose, can be converted to one of these 
intermediates. Glycolysis occurs, with variations, in nearly all organisms, both 
aerobic and anaerobic. The wide occurrence of glycolysis indicates that it is one of the 
most ancient known metabolic pathways [1]. 
In the aerobic metabolisms during the fasted state, the main destiny of the pyruvate 
molecules produced in the glycolysis is to entry into the tricarboxylix acid (TCA) 
cycle. In eukaryotic cells, the TCA cycle occurs in the matrix of the mitochondrion 
(Fig. 1.2.1). The TCA cycle is a series of eight chemical reactions used by all aerobic 
organisms to generate energy through the oxidation of acetate derived from 
carbohydrates, fats and proteins into carbon dioxide (CO2) and chemical energy in the 
form of ATP. The net yield for each molecule of glucose oxidized is two GTP 
(guanosine triphosphate), six NADH, two FADH2 (flavin adenine dinucleotide), six 
H+ e four CO2. In addition, the cycle provides precursors of certain amino acids as 
well as the reducing agent NADH that is used in numerous other biochemical 
reactions. Its central importance to many biochemical pathways suggests that it was 
one of the earliest established components of cellular metabolism. 
The acetyl-CoA, necessary for the TCA cycle is obtained not only by the glycolysis 
but also by the β-oxidation of the fatty acids. Fatty acids are transported across the 
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outer mitochondrial membrane by carnitine acyl transferases, and then couriered 
across the inner mitochondrial membrane by carnitine. Once inside the mitochondrial 
matrix, the fatty acyl-carnitine reacts with CoA to release the fatty acid and produce 
acetyl-CoA. Once inside the mitochondrial matrix, fatty acids undergo β-oxidation 
(Fig. 1.2.1). During this process, two-carbon molecules acetyl-CoA are repeatedly 
cleaved from the fatty acid. Acetyl-CoA can then enter the TCA, which produces 
NADH and FADH2. Since β-oxidation cleaves two-carbon molecules repeatedly, it 
works well for even carbon chain length saturated fatty acids. For odd-carbon chain 
length fatty acids and unsaturated fatty acids, a slightly different pathway is taken. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.1: Mitochondria are involved in many pathways belonged to energetic metabolism. 
 
All the oxidative degradation pathways described converge in the final step of the 
cellular respiration. During this process, all the energy produced is used to generate 
ATP. The oxidative phosphorylation (OXPHOS) represents the top of the energetic 
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metabolism for aerobic organisms. During OXPHOS, electrons are transferred from 
electron donors to electron acceptors such as oxygen, in redox reactions. These redox 
reactions release energy, which is used to form ATP. In eukaryotes, these redox 
reactions are carried out by a series of protein complexes within the cell's 
intermembrane wall mitochondria. The energy released by electrons flowing through 
this electron transport chain is used to transport protons across the inner 
mitochondrial membrane, in a process called electron transport. This generates 
potential energy in the form of a pH gradient and an electrical potential across this 
membrane. This store of energy is tapped by allowing protons to flow back across the 
membrane and down this gradient, through a large enzyme called ATP synthase 
(ATPase). This enzyme uses this energy to generate ATP from adenosine diphosphate 
(ADP), in a phosphorylation reaction. This reaction is driven by the proton flow, 
which forces the rotation of a part of the enzyme; the ATPase is a rotary mechanical 
motor. 
 
1.3	  Mitochondria	  
Mitochondria are ubiquitous membrane-bound organelles that are characteristic of the 
eukaryotic cell. Their functions are mediated by thousands of mitochondrial-specific 
proteins encoded by both the nuclear (nDNA) and mitochondrial (mtDNA) genome 
[2, 3]. The organelle is formed by a soluble matrix surrounded by a double membrane, 
an ion impermeable inner membrane, and a permeable outer membrane (Fig. 1.3.1) 
[4].  
Early biochemists documented the significance of mitochondria for aerobic oxidation 
of metabolic fuels, as they are the location of the electron transport chain (ETC) and 
OXPHOS that provides the majority of cellular energy in the form of ATP [5, 6]. 
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Figure 1.3.1: The basic structure of mitochondria. They are composed of an innemr 
membrane, an outer membrane and among them the intermembrane space. They have own 
circular molecule of DNA and ribosomes. The inner membrane is organized in cristae in 
order to increase the surface. 
 
It is now well established that they contribute to many other important functions 
including oxidative catabolism of amino acids, ketogenesis, ornithine cycle activity 
(“urea cycle”), the generation of reactive oxygen species (ROS) with important 
signaling functions [7, 8], the control of cytoplasmic calcium [9, 10], and the 
synthesis of all cellular Fe/S clusters, protein cofactors fundamental for cellular 
functions such as protein translation and DNA repair [11]. The rate-limiting first step 
in steroidogenesis is also located in mitochondria, associating mitochondrial function 
to endocrine homeostasis [12-15]. This collection of organelle functions justifies the 
variability in pathophysiology, severity, and age of onset of the increasing number of 
disorders associated to alterations in specific mitochondrial pathways [11, 16-18]. 	  
1.3.1	  Evolution	  of	  mitochondria	  
To comprehend nuclear–mitochondrial connections, we must take into consideration 
the early steps in the endosymbiontic event that generated the eukaryotic cell about 2 
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billion years ago [19]. In the beginning, the proto-nucleus–cytosol was restricted by 
energy. This limitation was relieved by its symbiosis with an oxidative α-
protobacterion, the proto-mitochondrion [20]. Consequently, growth and replication 
of the nucleus turn out to be regulated by mitochondrial energy production and thus 
calorie availability. This required the regulation of nuclear replication and gene 
expression by mitochondrial energetics. This was accomplished by joining alteration 
of nDNA chromatin structure and function by modification via high-energy 
intermediates: phosphorylation by ATP, acetylation by acetyl-CoA, deacetylation by 
NAD+ and methylation by S-adenosyl-methionine. Equally, the nucleus had to 
acquire mechanisms for modulating mitochondrial growth and replication. This was 
made complex by the successive transfer of genes from the proto-mtDNA to the 
nDNA, with the cytosolic translation products being directionally imported back into 
the mitochondrion [19]. This process continued over a billion years with the result 
that the nDNA-encoded genes of the mitochondrial genome are now disseminated 
throughout the chromosomes [19]. Hence, new mechanisms had to develop to 
coordinate the expression of the mitochondrial genes based on nuclear necessities for 
energy for growth and reproduction. As a result, this evolved in the development of 
inter-chromosomal coordinate transcriptional regulation. Over the subsequent 1.2 
billion years, the nucleus–cytosol became increasingly specialized in specifying 
structure while the mitochondrion became entirely dedicated to energy production 
[20]. 	  
1.3.2	  The	  dynamic	  morphology	  of	  mitochondria	  
Mitochondria are organized in a reticulum that is in continuous communication 
through dynamic fusion and fission events, moving actively throughout the cell 
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thanks to interactions with the cytoskeleton. The mitochondrial reticulum is 
constituted of an outer and an inner membrane, between which is the intermembrane 
space, and a matrix limited by the inner membrane (Fig. 1.3.1). The area of the inner 
membrane is greater than that of the outer membrane due to the presence of cristae, 
inner membrane invaginations that include all the transmembrane proteins of the ETC 
as well as the mitochondrial ATPase [21-23]. The mitochondrial matrix contains also 
the components of the TCA cycle and of the β-oxidation pathway. Mitochondrial 
fusion and fission not only merges the mitochondrial inner and outer membranes but 
also mixes mitochondria matrices and redistributes the mtDNAs [20].  
 
 
 
 
 
 
 
 
 
 
Figure 1.3.2: Overview of mitochondrial fusion and fission. A: A schematic showing 
mitochondrial fusion and fission. During fusion, there is merging of the mitochondrial outer 
membrane and inner membrane, resulting in mixing of the mitochondrial matrices. B: Live 
imaging illustrating that mitochondrial fusion results in content mixing. The mitochondria are 
labeled with DsRed and photoactivatable GFP. A mitochondrion is photoactivated (green) in 
the first frame and undergoes fission (arrow, second and third frames) followed by fusion 
(arrow, last frame)[24]. 
 
The mammalian mitochondrial fusion machinery includes three major proteins: 
mitofusin 1 (Mfn1), 2 (Mfn2), and the Optic Atrophy-1 Protein (Opa1) [25-27], while 
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the mitochondrial fission machinery engages dynamic-related protein 1 (Drp1), 
fission 1 (Fis1), and mitochondrial fission factor (Mff) [28-31]. Mitochondrial fission 
and fusion activities are both mediated by large guanosine triphosphatases (GTPases) 
in the dynamin family [32]. Their mutual actions divide and fuse the two lipid 
bilayers that surround mitochondria (Fig. 1.3.2). Fission is driven by the Mff-
mediated recruitment of Drp1 from cytosol to mitochondria in mammals [33], often at 
sites where mitochondria make contact with the endoplasmic reticulum [34]. Fusion 
between mitochondrial outer membranes is mediated by membrane-anchored 
dynamin family members named Mfn1 and Mfn2 in mammals, whereas fusion 
between mitochondrial inner membranes is mediated by a single dynamin family 
member called Opa1 in mammals [35]. Mitochondrial fission and fusion machineries 
are controlled by proteolysis and posttranslational modifications [32]. Frequencies of 
mitochondrial fission and fusion depend on variations in metabolism. Mitochondria 
are more fused when they have to rely on oxidative phosphorylation by withdrawing 
glucose as a carbon source [36]. Amplified fusion may be essential to increase the 
fidelity for oxidative phosphorylation by encouraging complementation among 
mitochondria. Starvation-induced autophagy may boost fusion by increasing the 
dependence on oxidative phosphorylation through the metabolism of lipids and 
proteins [36]. Otherwise, starvation may induce a specific stress response called 
stress-induced mitochondrial hyperfusion [37], or it may prevent fission in order to 
protect mitochondria from autophagic catabolism [38, 39]. Each of these outcomes is 
coherent with a model in which mitochondrial dynamics support the maximization of 
the oxidative phosphorylation under stressful conditions. 	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1.3.3	  mtDNA	  
Contrary to the nuclear genome, characterized of repetitive sequence families, introns, 
and vast intergenic regions, the mtDNA of mammals and other vertebrates shows 
remarkable economy of sequence organization [4]. The vertebrate mitochondrial 
genome is a closed circular molecule of ∼16.5 kb whose entire protein coding 
capacity is dedicated to the synthesis of 13 proteins that are essential subunits of 
respiratory complexes I, III, IV, and V [4]. The genes encoding complex II are 
entirely nuclear. The mtDNA also encodes the 22 tRNAs and 2 ribosomal RNAs 
essential for the translation of these respiratory subunits within the mitochondrial 
matrix. Mitochondrial genes miss introns and are arranged end on end with little or no 
intergenic regions [4]. Some respiratory protein genes overlay, and the adenine 
nucleotides of UAA termination codons are not encoded in the mtDNA but rather are 
delivered by polyadenylation following RNA processing [40]. Protein coding and 
rRNA genes are interspersed with tRNA genes that are assumed to determine the 
cleavage sites of RNA processing. The only substantial noncoding region is the D-
loop, named after the triple-stranded structure or displacement loop that is formed by 
association of the nascent heavy (H)-strand in this region (Fig. 1.3.3) [4]. The D-loop 
comprises the origin of heavy (H)-strand DNA replication and is also the site of 
bidirectional transcription from opposing heavy (HSP) and light (LSP) strand 
promoters [41]. Since mtDNA is a compartmentalized extra-chromosomal 
component, its inheritance model diverges from that of nuclear genes. Somatic 
mammalian cells generally have 103-104 copies of mtDNA with ∼2–10 genomes per 
organelle [42]. These genomes replicate in a relaxed fashion that is independent of the 
cell cycle that is defined by nuclear DNA replication [43, 44]. Some mtDNA 
molecules experience multiple rounds of replication while others do not replicate. 
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This, along with random sampling during cell division, permits the separation of 
sequence variants during mitosis [45]. Transcription of mtDNA is completely 
dependent on nucleus-encoded gene products. The transcription initiation complexes 
are comprised of a mitochondrial RNA polymerase (POLRMT), Transcription factor 
A (Tfam) and one of the two TFB isoforms (TFB1M and TFB2M) that function as 
dissociable specificity factors that contact both the polymerase and Tfam. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.3: Schematic representation of the human mitochondrial genome. Genomic 
organization and structural features of human mtDNA are depicted in a circular genomic map 
showing heavy (blue) and light (black) strands assigned as such based on their buoyant 
densities. Protein coding and rRNA genes are interspersed with 22 tRNA genes (red bars 
denoted by the single-letter amino acid code). Duplicate tRNA genes for leucine (L) and 
serine (S) are distinguished by their codon recognition (parentheses). The D-loop regulatory 
region contains the L- and H-strand promoters (LSP, HSP1, and HSP2), with arrows showing 
the direction of transcription. The origin of H-strand replication (OH) is within the D-loop, 
whereas the origin of L-strand replication (OL) is displaced by approximately two-thirds of 
the genome within a cluster of five tRNA genes (W, A, N, C, Y). Protein coding genes 
include the following: cytochrome oxidase (COX) subunits 1, 2, and 3; NADH 
dehydrogenase (ND) subunits 1, 2, 3, 4, 4L, 5, and 6; ATP synthase (ATPS) subunits 6 and 8; 
cytochrome b (Cyt b). ND6 and the 8 tRNA genes transcribed from the L-strand as template 
are labeled on the inside of the genomic map, whereas the remaining protein coding and RNA 
genes transcribed from the H-strand as template are labeled on the outside [4]. 
 
In mammals, mtDNA is maternally inherited [45, 46]. Usually, paternal mtDNA is 
lost during the first few embryonic cell dissections and does not give mtDNA to the 
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progeny, although there are reports of the occurrence of the paternal heredity in 
somatic tissues [47]. Once, recombination between maternal and paternal genomes 
has been recognized [48]. Furthermore, because mtDNA is a multicopy genome, an 
individual may show more than a single sequence, a condition named heteroplasmy. 
A harmful sequence variant may be tolerated in low copy because the defective gene 
product(s) it encodes do not reach the threshold for disrupting cellular function. 
Conversely, sequence variants are recognized to separate rapidly from heteroplasmy 
to homoplasmy in passing from one generation to the next [49]. This could end with 
offspring in which the detrimental variant prevails, running to a defective 
mitochondrial phenotype. 	  
1.3.4	  Oxidative	  phosphorylation	  	  
The ETC is constituted of four large multisubunit complexes (complexes I to IV) with 
more than 85 individual gene products and ATPase (complex V). The proteins that 
compose the different complexes are both nuclear and mitochondrial encoded except 
the complex II that is completely nuclear. In Table 1 the number of subunits for each 
complex that are nucleus or mitochondria encoded are reported [50]. 
Table 1: Number of nuclear- and mitochondrial-encoded electron transport chain proteins. 
 
The ETC transfers electrons from donors (NADH at complex I, FADH2 at complex 
II) to a final acceptor, molecular oxygen, forming H2O at complex IV [51]. Two 
electrons (reducing equivalents from hydrogen) are transferred from NADH + H+ to 
 Complex I Complex II Complex III Complex IV Complex V 
mtDNA 7 0 1 3 2 
nDNA 39 4 10 10 14 
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the OXPHOS complex NADH dehydrogenase (complex I) or from FADH2 to the 
succinate dehydrogenase (SDH, complex II) to reduce ubiquinone (coenzyme Q10, 
CoQ) to ubiquinol CoQH2 [20]. The electrons from CoQH2 are transferred 
successively to complex III (bc1 complex), cytochrome c, complex IV (cytochrome c 
oxidase, COX), and finally to oxygen (1⁄2O2) to give H2O [20]. The energy that is 
liberated during the electrons’ flow is used to pump protons out across the 
mitochondrial inner membrane through complexes I, III, and IV creating a proton 
electrochemical gradient; the remainder is dissipated as heat (Fig. 1.3.4). The energy 
contained in the proton electrochemical gradient generated by the ETC is then 
coupled to ATP production as protons flow back into the matrix through the 
mitochondrial ATPase (Complex V). Matrix ATP is then exchanged for cytosolic 
ADP by the inner membrane adenine nucleotide translocators [20]. 
 
 
 
 
 
Figure 1.3.4: The mammalian oxidative phosphorylation (OXPHOS) system. Depicted are the 
four respiratory complexes (I–IV), electron carriers coenzyme Q and cytochrome c, the ATP 
synthase complex, the ADP/ATP carrier and the phosphate carrier (PiC). Arrows at 
complexes I, III, and IV illustrate the proton pumping to the intermembrane space.  
 
Thus, OXPHOS results from electron transport, the generation of a proton gradient, 
and subsequent proton flux coupled to the mitochondrial ATPase [51]. Each of these 
steps can vary in efficiency; for example, the exact stoichiometry between electron 
flow and proton pumping, or between proton pumping and ATP synthesis varies 
depending on the probability of loss of electrons from the ETC before reaching 
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complex IV and on non-ATPase-coupled proton leak through the inner mitochondrial 
membrane (e.g., via uncoupling proteins (UCPs)) [51]. The high electronegative 
potential produced by the proton gradient also forces the rapid entry of Ca++ into the 
mitochondrial matrix, protecting its concentration in the cytoplasm. In the 
mitochondrial matrix, Ca++ can stimulate flux through the TCA cycle by rising 
dehydrogenase activities [10]. The exit of Ca++ from the matrix is driven by 
electroneutral exchange with Na+ or H+. 
The efficiency by which dietary reducing equivalents are converted to ATP by 
OXPHOS is known as the coupling efficiency [20]. This is determined by the 
efficiency by which protons are pumped out of the matrix by complexes I, III, and IV 
and the efficiency by which proton flux through complex V is converted to ATP [20]. 
The uncoupler compounds like 2,4-dinitrophenol (DNP) or carbonyl cyanide rn-
chlorophenylhydrazone (CCCP) and the nDNA-encoded UCP1 and 2 render the 
mitochondrial inner membrane leaky for protons, by-passing complex V and 
dissipating the energy as heat [19]. 
 
1.3.5	  ROS	  and	  mitochondria	  
The ETC is a strong font of ROS. ROS production is more expected to happen when 
the proton gradient is large and electron carriers are highly reduced, e.g., when ADP 
is rate limiting for ATP generation or when availability of O2 is restrictive. 
Uncoupling proteins are pondered to be natural regulators of this process, replying to 
and governing ROS production by alleviating the establishment of a large proton 
gradient. Under normal physiological conditions, ROS production is highly 
structured, at least in part controlled by complex I [52-54]. Though, when the ETC 
turns out to be highly reduced, the excess electrons can be delivered directly to O2 to 
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produce superoxide anion (O2-). The O2- generated by complex I is discharged into the 
mitochondrial matrix where it is transformed to hydrogen peroxide (H2O2) by the 
matrix manganese superoxide dismutase, MnSOD (Sod2 gene). Superoxide produced 
from complex III is liberated into the mitochondrial intermembrane space where it is 
converted to H2O2 by Cu/ZnSOD (Sod1) which is located in the mitochondrial 
intermembrane space and cytosol [20]. Mitochondrial H2O2 can diffuse into the 
nucleus–cytosol. If H2O2 faces a reduced transition metal or is mixed with O2-, the 
H2O2 can be further reduced to hydroxyl radical, the most potent oxidizing agent of 
the ROS. ROS can impair cellular proteins, lipids, and nucleic acids. Hereafter, 
excessive mitochondrial ROS generation can exceed the antioxidant protections of the 
cell, and the cumulative injury can ultimately lead to cell death [20]. 	  
1.3.6	  Apoptosis	  and	  mitochondria	  
 Apoptosis mediates catabolism of eukaryotic cells and it is a process crucial for the 
development and the turnover of tissues, for the mechanisms of cellular defense and 
protection from cancer. All apoptotic pathways converge to the activation of caspases, 
proteases that orchestrate the efficient cell elimination without causing inflammation. 
Two pathways have been characterized by which caspases are activated: the extrinsic 
pathway that is mediated by some membrane receptors, which directly activate 
caspase 8, and the intrinsic pathway that originates from the mitochondria. 
Mitochondria control an apoptotic phase, which precedes the activation of caspases 
and which is regulated by proteins belonging to the family of B-cell lymphoma 2 
(Bcl-2). It is well documented, that the role of mitochondria in the activation of 
caspases is accomplished through the release of these proteins from the 
intermembrane space to the cytosol. When cytochrome c is released from 
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mitochondria binds to the apoptotic protease activating factor 1 (APAF1), initiating 
the assembly of the apoptosome, which is responsible for the activation of caspase 9 
[55]. In literature it is well established, that during the apoptotic phenomenon 
mitochondria fragment into many small units, although it is not yet fully clear 
whether this occurs before or simultaneously with activation of caspases. It has been 
demonstrated that the blocking of this unregulated fission inhibits the release of 
cytochrome c and delays cell death, connecting the morphogenic machinery of these 
organelles to the programmed cell death [56]. Excessive mitochondrial fission appears 
to be a necessary requirement in intrinsic apoptotic pathway, at least for the release of 
cytochrome c and the caspase activation. On the other hand, apoptosis can be 
inhibited, by the mitochondrial fusion. Some proteins involved in mitochondrial 
fusion machinery are in some way linked to apoptosis. The silencing of Mfn1 and 
Mnf2 results in excessive mitochondrial fragmentation and increased sensitivity to 
proapoptotic stimuli [57].  
An early mark of apoptosis is the mitochondrial membrane potential decrease [58]. It 
activates, the mitochondrial permeability transition pore (mtPTP), the mitochondrial 
self-destruct system [59]. mtPTP is also stimulated when the biochemical condition of 
the mitochondria and cell regress, specifically when mitochondrial energy production 
declines, ROS generation increases, and excessive Ca++ is discharged into the cytosol 
and taken up by the mitochondrion [20]. When the mtPTP is activated, it unlocks a 
channel in the mitochondrial inner membrane, short circuits proton electrochemical 
gradient, and initiates programmed cell death (apoptosis) [60].  
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1.4	  Transcriptional	  control	  mechanisms	  of	  mitochondria	  
Although we know very little about specific mechanisms that control different 
modalities of mitochondrial biogenesis, it is clear that these mechanisms require 
coordination between the nuclear and mitochondrial genomes. Transcription of the 
mitochondrial genome is under the control of a single transcription factor, Tfam, 
which is encoded by the nuclear genome [51]. In turn, Tfam expression is controlled 
by the nuclear transcription factors 1 (NRF-1) and 2 (NRF-2), which specifically 
activate abundant nuclear-encoded genes implicated in mitochondrial respiration [61, 
62] (Fig. 1.4.1). Thus, through NRF-stimulated expression of Tfam, the transcription 
of the mitochondrial genome is stimulated in coordination with that of nuclear-
encoded mitochondrial genes [51]. The expression of many other mitochondrial genes 
is coordinated by additional nuclear transcription factors, like peroxisome 
proliferator-activated receptor α (PPARα), PPARδ, estrogen-related receptor (ERR) α 
/γ, and Sp1 (Fig. 1.4.1), which can stimulate the mitochondrial genes’ expression in a 
tissue-dependent and physiological context-dependent manner [50]. A high level of 
transcriptional coordination is required to ensure coupling of mitochondrial activity to 
other metabolic activities within the cell and to mediate appropriate parallel changes 
in all components of multiprotein complexes [51]. This coordination is achieved 
through the action of transcriptional coactivators and corepressors. The most-known 
coactivators of mitochondrial gene transcription are members of the PPARγ 
coactivator (PGC) family, including PGC-1α, PGC-1β [63, 64], and PPRC, a related 
serum-responsive coactivator [65] (Fig. 1.4.1). These act in response to cellular 
energy-requiring states such as cell growth, hypoxia, glucose deprivation, and 
exercise [50] to promote transcription factors involved in mitochondrial remodeling 
and/or biogenesis, thus restoring cellular energetics. For instance, PCG-1α is highly 
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expressed in muscle, liver, and brown fat, and its expression is further increased in 
these tissues in response to exercise, fasting, and cold exposure, respectively [51]. 
Although PGC-1α and β do not seem to be essential for mitochondrial biogenesis 
during development [66], they are required for the expression of the entire set of 
proteins necessary for mitochondrial OXPHOS and fatty acid β-oxidation pathways in 
muscle and brown adipose tissue [67-76]. Additionally, PGC-1α and PGC-1β are 
critical for the rapid bursts in mitochondrial proliferation that is associated with 
perinatal heart and brown adipose tissue development [66]. These considerations 
sustain the idea that mitochondrial adjustment to specific energy needs is regulated by 
PGC-1α and PGC-1β. Conversely, mitochondrial development during cell 
proliferation is more likely to rely on serum-responsive coactivators such as PPRC 
[77]. The role of corepressors in the transcriptional control of energy metabolism 
genes is less extensively studied [51]. Nevertheless, evidence in cultured cells and in 
mouse models supports the critical role of the corepressor RIP140 in controlling 
mitochondrial energy metabolism in both adipose tissue and muscle [78-82]. RIP140 
inhibits UCP1 through interaction with specific enhancer elements and also avoids 
expression of genes associated with β-oxidation and respiratory chain assembly. 
RIP140 also interacts directly with many of the transcription factors coactivated by 
PGC-1α [83]. The mechanisms that control the balance between PGC-1 coactivators 
and RIP140 and other corepressors are not clear but are likely to represent key 
regulatory mechanisms of energetic adaptation [51]. 
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Figure 1.4.1: Basic structural and functional features of the mitochondrial reticulum. The 
mitochondrial reticulum is composed of an inner and outer membrane, between which lies the 
intermembrane space, and a matrix contained within the inner membrane. The surface of the 
inner membrane is folded into cristae. The organization and distribution of the mitochondrial 
reticulum is controlled by interactions with cytoskeletal elements such as microtubules. The 
matrix contains the enzymatic machinery for fatty acid β-oxidation, which generates acetyl-
CoA from acyl chains, and reducing equivalents in the form of NADH and FADH2 in the 
process. Acetyl-CoA fuels the TCA cycle, which also produces NADH and FADH2. These 
donate electrons to the ETC, leading to the generation of a proton gradient across the inner 
mitochondrial membrane. Dissipation of this gradient through the mitochondrial ATPase 
generates ATP. Delay of electron transport by the ETC results in the production of ROS, 
which can activate UCPs that dissipate the proton gradient without producing ATP. The 
electrochemical gradient also causes cytoplasmic Ca++to enter the matrix, buffering 
cytoplasmic Ca++ levels and promoting TCA cycle flux. Mitochondria are also crucial in the 
generation of iron-sulfur clusters that form the prosthetic group of numerous proteins 
involved in multiple cellular pathways. The mitochondrial reticulum undergoes continuous 
fusion and fission reactions that involve both the inner and outer mitochondrial membranes, 
allowing redistribution of matrix content, such as mtDNA, within the reticulum. Both 
mitochondrial and nuclear DNA encoded the proteins composing all mitochondrial 
machineries. The master transcription factor operating on mtDNA is Tfam, which is encoded 
in the nuclear genome. The expression of mitochondrial genes in the nucleus is driven by 
numerous transcription factors, which are in turn controlled by specific coactivators and 
corepressors that respond to cellular energy demands [51]. 
 
1.4.1	  Tfam	  
Tfam was first recognized as a high mobility group (HMG)-box protein that promote 
transcription through specific binding to recognition sites upstream from both light 
(LSP) and heavy (HSP) strand promoter [84]. Structurally, it consists of two tandemly 
arranged HMG motifs and a COOH-terminal tail [4]. Tfam looks like other HMG 
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proteins, as it can bend and unwind DNA, properties potentially connected to its 
ability to promote transcription upon binding DNA [85, 86]. Tetrameric binding of 
Tfam to its recognition site is known to stimulate bidirectional transcription by 
facilitating symmetrical interactions with other transcriptional components [87]. In 
addition to specific promoter recognition, Tfam binds nonspecifically to apparently 
random sites on mtDNA [85, 88]. This property, along with its abundance in 
mitochondria, suggests that it plays a role in the stabilization and maintenance of the 
mitochondrial chromosome [4]. The transcriptional activation function of Tfam 
belongs to a COOH-terminal activation domain that is necessary both for 
transcriptional ability and for specific binding to promoter recognition sites [89]. 
Tfam knockout mice show embryonic lethality and a reduction of mtDNA 
corroborating a crucial role for the protein in mtDNA maintenance in mammals [90]. 
Intriguingly, Tfam levels associate well with increased mtDNA in ragged-red muscle 
fibers, fibers showing an excessive proliferation of abnormal mitochondria, and 
decreased mtDNA levels in mtDNA-depleted cells [91]. This evidence correlates with 
the observation that transgenic mice overexpressing human Tfam show increased 
mtDNA copy number [92]. The mtDNA amount determined in somatic tissues and in 
embryos is relative to those of Tfam expressed in each, advocating that Tfam could be 
a limiting factor of mtDNA copy number. Thus its properties implicate Tfam as an 
ideal target for regulatory pathways that control both mtDNA maintenance and 
transcriptional expression [4]. 
In addition to its role in transcription initiation, Tfam binds abundantly and non-
specifically around the entire mitochondrial genome [93]. In vivo, mtDNA exists as 
discrete, punctate protein–DNA structures named nucleoids. Tfam is a major 
component of the nucleoid [94-96], where it   an architectural [97] or scaffolding [92] 
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role, apparently through its strong affinity for non-specific DNA sequences [88]. 
Several models have been stated to clarify how Tfam regulates genome compaction 
and promoter activity [97-102]. Fig. 1.4.2 provides a series of illustrations of Tfam 
dimer-mediated genome compaction with increasing Tfam loading by a non-specific, 
cooperative mechanism as Tfam abundance increases [93]. Because the abundance of 
Tfam in nucleoids can vary considerably without affecting nucleoid volume [103-
105], the loops formed at low Tfam occupancy were considered to be the primary 
mechanism for the maintenance of mtDNA contour length [93]. As Tfam 
concentration increases, cooperatively drives Tfam loading at proximal sites, 
increasing the rigidity and density of the structure [93].  
 
 
 
 
 
 
Figure 1.4.2: Tfam binding: dimerization, formation of loop structures, and genome 
compaction. Tfam concentration increases from the left to the right of the illustration 
(indicated by blue triangle). All binding events are considered non-specific and are not to 
scale. Because this model assumes dimeric Tfam bound to DNA, the subunit bound to DNA 
is shown in dark blue and the unbound subunit is in light blue. At low concentrations Tfam 
dimers bind to form loop structures that reduce DNA contour length (both subunits are shown 
in dark blue, indicating DNA binding by both subunits in the dimer to form a loop). 
Cooperative binding stimulates preferential Tfam loading at sites proximal to previously 
bound Tfam molecules (sites shown in green), until maximal compaction is achieved at 
highest Tfam concentrations. Limited genome access at these maximally compacted 
molecules could minimize transcription or replication activity [93]. 
 
 
The additional structural rigidity is likely imparted by topological changes in the 
genome, with some contour length reduction occurring through bending and 
supercoiling [85, 93, 106, 107]. Based on the evidences that high Tfam:mtDNA ratios 
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decline mtDNA copy number [108, 109] in vivo, true saturation of Tfam would likely 
drive to biologically inactive (quiescent) genomes [98]. The large number of genomes 
within the cell would allow for some molecules to exist in this “off” state; tissues 
with lower relative oxidative metabolism, or those in which primary cells are not 
dividing, might be able to maintain a greater percentage of quiescent mtDNA without 
ending in some sort of illnesses [93]. The mtDNA:Tfam ratio is controlled by the 
mitochondrial Lon protease that regulates the mtDNA copy number and transcription 
by selective degradation of Tfam [109]. 	  
1.4.2	  NRF-­‐1/	  NRF-­‐2	  
NRF-1 is a nuclear encoded transcription factor linked to the expression of many 
genes involved in mitochondrial respiratory function as the vast majority of nuclear 
genes that encode subunits of the five respiratory complexes [110-112]. Moreover, 
considerable data sustains a potential integrative role of NRF-1 in coordinating 
respiratory subunit expression with that of the mitochondrial transcriptional 
machinery [4]. As illustrated in Figure 1.4.3, NRF-1 activates the Tfam promoter 
[61], a major regulator of mitochondrial transcription. NRF-1 is also related to the 
expression of key enzymes of the heme biosynthetic pathway [113, 114]. Moreover, 
NRF-1 acts on genes whose functions are not restricted to the bigenomic expression 
of the respiratory apparatus (Fig. 1.4.3) [4]. For example, NRF-1 regulates key 
constituents of the protein import and assembly machinery in mitochondria. This 
proposes a broader function for the factor in coordinating mitochondrial biogenesis 
beyond the transcriptional expression of the respiratory chain. This hypothesis is 
strengthened by reports that relate rises in NRF-1 mRNA or DNA binding activity 
with generalized effects on mitochondrial biogenesis [4]. It is worth to notice that 
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NRF-1 targets are not limited to genes involved in mitochondrial function. Among 
these are genes encoding metabolic enzymes, components of signaling pathways, and 
gene products necessary for chromosome maintenance and nucleic acid metabolism 
among others. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.3:Diagrammatic summary of the nuclear control of mitochondrial functions by 
NRF-1 and NRF-2 (GABP). NRFs contribute both directly and indirectly to the expression of 
many genes required for the maintenance and function of the mitochondrial respiratory 
apparatus. NRFs act on genes encoding cytochrome c, the majority of nuclear subunits of 
respiratory complexes I–V, and the rate-limiting heme biosynthetic enzyme 5-
aminolevulinate synthase. In addition, NRFs promote the expression of key components of 
the mitochondrial transcription and translation machinery that are necessary for the 
production of respiratory subunits encoded by mtDNA. These include Tfam, TFB1M, and 
TFB2M as well as a number of mitochondrial ribosomal proteins and tRNA synthetases. 
Recent findings suggest that NRFs are also involved in the expression of key components of 
the protein import and assembly machinery [50]. 
	  
A second nuclear factor designated as NRF-2 or GABP was recognized based on its 
specific binding in the cytochrome oxidase subunit IV (COXIV) promoter [62]. In 
addition to the COX promoters, functional NRF-2 sites have been identified in a 
number of other genes connected to respiratory chain expression [110, 111]. Hence, 
like NRF-1, NRF-2 contributes in the coordination of the expression profile of 
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essential respiratory chain proteins with key components of the mitochondrial 
transcription machinery [4]. Such a mechanism may serve to ensure the coordinate 
bigenomic expression of respiratory subunits.	  	  
1.4.3	  PGC-­‐1α	  
PGC-1α, the best-studied member of a family of transcriptional coactivators, was 
identified in a differentiated brown fat cell line on the basis of its interaction with 
PPARγ, an important regulator of adipocyte differentiation [115]. The remarkable 
induction of PGC-1α mRNA in brown fat upon cold exposure sustains its role in 
thermogenic regulation [116, 117]. A relevant aspect of the thermogenic program is 
the stimulation of mitochondrial biogenesis, and PGC-1α is a great inducer of this 
process [4]. Ectopic overexpression of the coactivator in cultured myoblasts and other 
cells stimulates respiratory subunit mRNAs and increases COXIV and cytochrome c 
protein levels as well as the steady-state level of mtDNA [63]. As illustrated in Figure 
1.4.4, NRF-1 has been identified as an important target for the induction of 
mitochondrial biogenesis by PGC-1α. The coactivator binds NRF-1 and can trans-
activate NRF-1 target genes involved in mitochondrial respiration [4]. In addiction, a 
dominant negative allele of NRF-1 inhibits the effects of PGC-1α on mitochondrial 
biogenesis providing in vivo evidence for a NRF-1-dependent pathway [63]. PGC-1α 
may connect nuclear regulatory events to the mitochondrial transcriptional machinery 
through its transcriptional activation of Tfam. As with respiratory subunit genes, the 
coactivator targets the NRF-1 and NRF-2 recognition sites within Tfam promoter 
leading to increased mRNA expression [118]. Estrogen related receptor α (ERRα) and 
NRF-2α recognition sites are conserved in the promoters of a number of oxidative 
phosphorylation genes, including cytochrome c and β-ATP synthase, and PGC-1α can 
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drive expression through these sites [119, 120] (Fig. 1.4.4). In addition to its role on 
the respiratory chain and mitochondrial transcription, PGC-1α stimulates 
mitochondrial oxidative functions by promoting the expression of genes of the 
mitochondrial fatty acid oxidation and heme biosynthetic pathways [4] (Fig. 1.4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.4: Illustration summarizing PGC-1α-mediated pathways governing mitochondrial 
biogenesis and function. Depicted in the nucleus (shaded sphere) are the key transcription 
factors (NRF-1, NRF-2, ERRα, PPARα, and MEF-2) that are PGC-1α targets and act on 
nuclear genes governing the indicated mitochondrial functions. Some of the physiological 
effector pathways mediating changes in the transcriptional expression or function of PGC-1α 
are also shown. The CREB activation of PGC-1α gene transcription in response to cold 
(thermogenesis), fasting (gluconeogenesis), and exercise has been well documented. The 
physiological mechanisms of PGC-1α induction by nitric oxide are not established but may 
involve the production of endogenous nitric oxide by eNOS. A potential pathway of 
retrograde signaling through calcium is also included [50]. 
 
 
Physiological expression of PGC-1α at the transcriptional level can be modulated 
through cAMP-dependent signaling [4]. The PGC-1α promoter has a potent cAMP 
response element (CRE) that works as a target for CREB-mediated transcriptional 
activation [121]. PGC-1α along with Tfam and NRF-1 are induced via cGMP-
dependent signaling resulting from elevated levels of nitric oxide (NO) [122] (Fig. 
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1.4.4). The NO induction of PGC-1α is correlated with increased mitochondrial bio- 
genesis in several cell lines [4]. The induced mitochondrial mass is complemented by 
increased oxidative phosphorylation-coupled respiration consistent with an induced in 
functional mitochondria [123]. A number of reports associate the expression of PGC-
1α to exercise-induced mitochondrial biogenesis in skeletal muscle [124-128]. In each 
case, PGC-1α mRNA and/or protein increase as an adaptive response to endurance 
exercise of varying intensity and duration.	  	  	  
1.5	  Patophysiology	  
In the last 20 years, mitochondrial dysfunction has been recognized as an important 
promoter of human pathologies. Mitochondrial defects play a direct role in certain 
well-defined neuromuscular diseases and are also thought to contribute indirectly to 
many degenerative diseases [4]. Mutations in mitochondrial genes for respiratory 
proteins and translational RNAs, particularly tRNAs, show themselves in a wide 
range of clinical conditions, most of which affect the neuromuscular system [60, 129]. 
These mtDNA mutations are often maternally inherited, and in some cases, patients 
with certain mitochondrial myopathies display excessive proliferation of abnormal 
mitochondria in muscle fibers, the so-called ragged red fiber [130]. In addition, a 
subset of mitochondrial diseases exhibits a Mendelian inheritance pattern typical of 
nuclear gene defects [4]. These can impair respiratory protein subunits, assembly 
factors, and gene products necessary for mtDNA maintenance and stability [131, 
132]. In addition to single gene defects, dispersed lesions in mtDNA that accumulate 
over time may be involved in human pathologies including neurodegenerative 
diseases [133], diabetes [134], and ageing [135].  
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1.5.1	  Neurodegenerative	  diseases	  
It has been widely speculated that free radical production by the mitochondrial 
respiratory chain contributes to the neuropathology observed in dementia and other 
degenerative diseases [4]. Although there is positive evidence for oxidative stress 
associated with neuropathology, it has been difficult to prove whether this is a cause 
or a consequence of neuronal death [136]. Parkinson's disease (PD) is the most 
common movement disorder and is characterized primarily by the loss of 
dopaminergic neurons in the substantia nigra pars compacta leading to a dopamine 
deficit in the striatum (). The consequent dysregulation of basal ganglia circuitries 
explains the most prominent motor symptoms, including rigidity, resting tremor and 
postural instability. A pathological hallmark of sporadic PD is the occurrence of 
proteinaceous deposits within neuronal perykarya (Lewy bodies) and processes (Lewy 
neurites), mainly constituted of α-synuclein, ubiquitin, neurofilaments and molecular 
chaperones [137]. Little is known about the etiopathogenesis of PD. Accumulating 
evidence suggests that PD-associated genes directly or indirectly impinge on 
mitochondrial integrity, for example the MTPT compound (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine), an ETC complex I inhibitor, was found to induce 
Parkinson in humans [138, 139]. Moreover, oxidative stress is found to have a role in 
neuronal degeneration of the dopaminergic neurons [140]. The most common 
sporadic form of PD looks like a complex multifactorial disorder with variable 
influences of environmental factors and genetic susceptibility. A major breakthrough 
in PD research was the identification of genes that are responsible for monogenic 
familial forms. Mutations in the genes encoding α-synuclein and LRRK2 (leucine-
rich repeat kinase 2) are accountable for autosomal dominant forms of PD, apparently 
by a gain-of-function process. Increased α-synuclein expression as well as α-
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synuclein deficiency may be associated with mitochondrial irregularities like 
ultrastructural abnormalities, impaired COX and complex IV activity, reduced 
complex I/III activity, a decline in the mitochondrial membrane potential, oxidation of 
mitochondria-associated metabolic proteins, and an amplified sensitivity to 
mitochondrial toxins [141-146]. LRRK2 can bind to the outer mitochondrial 
membrane in mammalian brain and about 10% of overexpressed LRKK2 was found 
in association with the outer mitochondrial membrane. Nevertheless, it remains to be 
investigated whether LRRK2 has an influence on mitochondrial integrity [140]. 
Loss-of-function mutations in the genes encoding parkin and PINK1 mediate 
autosomal recessive PD. Sporadic and monogenic forms share important clinical, 
pathological and biochemical characters, notably the progressive demise of 
dopaminergic neurons in the substantia nigra [140]. Several studies examined 
mitochondrial features in tissues from parkin-mutant patients. An important reduction 
(by about 60%) in complex I activity was discovered both in patients with parkin 
mutations and sporadic PD patients, whereas complex IV activity was only impaired 
in sporadic PD patients. Cultured fibroblasts from parkin mutant patients presented 
morphological and functional mitochondrial deficiencies, for instance a reduction in 
the membrane potential (by 30%), complex I activity (by 45%), ATP production (by 
58%) and a rise in rotenone-induced mitochondrial fragmentation [147]. In another 
report parkin mutant fibroblasts were characterized by a 22% decrease in the mtDNA 
copy number and an increased vulnerability to oxidative stress-induced mtDNA 
impairment [148]. The consequences of PINK1 deficiency on mitochondrial function 
and morphology are multidimensional, including decreases in mitochondrial 
membrane potential, complexes I and IV activities, ATP production, mitochondrial 
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import and mtDNA levels, increases in ROS production and abnormal ultrastructural 
mitochondrial morphology [18, 149-151]. 	  
1.5.2	  Aging	  
The accumulation of mutations in mtDNA is also thought to contribute to human 
aging [4]. Alterations in mtDNA, comprising increased occurrence of point mutations 
and deletions, have been documented in aged individuals [152] and mice [153]. The 
declining in the somatic mtDNA mutations rate by introducing catalase into the 
mitochondrial matrix lengthens mouse life span [154]. These observations along with 
the known age-related reduction in oxidative energy metabolism has suggested that 
mtDNA mutations impair the respiratory chain driving to a decreased oxidative 
phosphorylation [135]. 
 
1.5.3	  Type	  2	  diabetes	  
There has also been considerable interest in mitochondrial dysfunction as a 
contributing factor in the onset of type 2 diabetes (T2D)[155]. Although the primary 
cause of this disease is unknown, it is clear that insulin resistance plays an early role 
in its pathogenesis and that defects in insulin secretion by pancreatic β cells are 
instrumental in the subsequent progression to hyperglycemia. Indeed, several lines of 
evidence indicate that insulin resistance is an early feature of T2D. Petersen et al. 
found that in comparison with matched young controls, healthy lean elderly subjects 
had severe insulin resistance in muscle, as well as significantly higher levels of 
triglycerides in both muscle and liver [156]. These changes were accompanied by 
decreases in both mitochondrial oxidative activity and mitochondrial adenosine 
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triphosphate (ATP) synthesis. These data support the hypothesis that insulin 
resistance in humans’ skeletal muscle arises from defects in mitochondrial fatty acid 
oxidation, which in turn lead to increases in intracellular fatty acid metabolites (fatty 
acyl CoA and diacylglyerol) that disrupt insulin signaling (Fig. 1.5.1) [134].  
 
 
 
 
 
 
 
 
 
 
Figure 1.5.1: Potential mechanism by which mitochondrial dysfunction induces insulin 
resistance in skeletal muscle. In the depicted model, a decrease in mitochondrial fatty acid 
oxidation, caused by mitochondrial dysfunction and/or reduced mitochondrial content, 
produces increased levels of intracellular fatty acyl CoA and diacylglycerol. These molecules 
activate novel protein kinase C, which in turn activates a serine kinase cascade possibly 
involving inhibitor of nuclear factor kB kinase (IKK) and c-Jun N-terminal kinase 1, leading 
to increased serine phosphorylation (pS) of insulin receptor substrate–1 (IRS-1). Increased 
serine phosphorylation of IRS-1 on critical sites (e.g., IRS-1 Ser307) blocks IRS-1 tyrosine 
(Y) phosphorylation by the insulin receptor, which in turn inhibits the activity of phosphatidyl 
inositol 3-kinase (PI 3-kinase). This inhibition results in suppression of insulin-stimulated 
glucose transport, the process by which glucose is removed from the blood. PIP3 indicates 
phosphatidylinositol 3,4,5-trisphosphate; PTB, phosphotyrosine binding domain; PH, 
pleckstrin homology domain; SH2, src homology domain [134]. 
 
Insulin resistance in healthy aged individuals with no family history has been 
correlated with a decline in mitochondrial oxidative phosphorylation [156]. The 
expression of a number of genes involved in oxidative metabolism is reduced in 
diabetic subjects as well as in those predisposed to diabetes because of family history 
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[157, 158]. In addition, in comparison with insulin-sensitive controls, the insulin-
resistant subjects were found to have a lower ratio of type I to type II muscle fibers. 
Type I fibers are mostly oxidative and contain more mitochondria than type II muscle 
fibers, which are more glycolytic. Conceivably, these individuals may have fewer 
muscle mitochondria, possibly because of decreased expression of nuclear-encoded 
genes that regulate mitochondrial biogenesis, such as PGC-1α [63] and PGC-1β 
[159]. Microarray studies support this hypothesis since PGC-1α–responsive genes are 
down-regulated in the skeletal muscle of obese Caucasians with impaired glucose 
tolerance and T2D [158], and PGC-1α and PGC-1β are themselves down-regulated in 
the skeletal muscle of both obese diabetic and overweight non diabetic Mexican-
Americans [157]. Alternatively, the reduction in mitochondrial oxidative 
phosphorylation activity in insulin-resistant individuals could be due not to 
mitochondrial loss but rather to a defect in mitochondrial function. This hypothesis is 
supported by muscle biopsy studies. In one study, the activity of mitochondrial 
oxidative enzymes was found to be lower in T2D subjects [160], and in another, the 
activity of mitochondrial rotenone-sensitive nicotinamide adenine dinucleotide 
oxidoreductase was found to be lower [161]. Because obese individuals have also 
been shown to have smaller mitochondria with reduced bioenergetic capacity 
compared with lean controls [161], the mitochondrial abnormalities in these subjects 
might be related to obesity rather than to insulin resistance. 
Although insulin secretion is also modulated by a number of stimuli that operate 
outside this pathway, it is clear that oxidative mitochondrial metabolism is central to 
glucose-stimulated insulin secretion [162]. The critical role of mitochondria is evident 
from the rare hereditary disorders in which diabetes with β cell dysfunction has been 
traced to specific mutations in the mitochondrial genome [162, 163]. Given the 
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central role of mitochondria in glucose sensing, it is possible that decreased 
mitochondrial function in β cells, might predispose individuals to develop β cell 
dysfunction and T2D.  
These associations of mitochondrial dysfunction with human degenerative disease 
raise the basic question of how mammalian cells control mitochondrial biogenesis. It 
has become increasingly apparent that transcriptional mechanisms contribute to the 
biogenesis of mitochondria including the expression of the respiratory apparatus. 
Unfortunately, little is known about the link between mitochondria and many 
diseases, about the mitochondrial regulation and about the cross-talk between the 
nucleus and the mitochondria.  
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2.	  Aim:	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As sites of the main oxidative reactions and of the electron transport chain, 
mitochondria are the organelle committed to metabolic energy production required for 
all cellular functions. Mitochondria possess an own genome, whose replication and 
transcription is nuclear-mediated through the Tfam. Most of the mitochondrial 
proteins are nuclear-encoded, too. Consequently the nuclear-mitochondrial crosstalk 
is at the base for mitochondrial biogenesis and function. The mitochondrial biogenesis 
is the process through which new mitochondria are created and a hallmark of this 
event is the increase in the mtDNA content. For the mitochondrial function or activity 
instead, we intend all the processes mitochondria have to deal with, and the most 
important one is the ATP production. Because of the ubiquitous presence of 
mitochondria in all tissues, their density and function have a significant impact on 
whole-body metabolism. Deficiency in energy metabolism has emerged as a possible 
explanation for the etiology of complex diseases over the past 20 years [20]. The 
primary limiting factor for growth and reproduction of all biological systems is 
energy and the first report that mtDNA mutations can cause disease [164-169] have 
been followed by reports that a broad spectrum of metabolic and degenerative 
diseases can have a mitochondrial etiology. In fact, a mitochondrial dysfunction is 
associated to many disorders such as insulin resistance, diabetes and Parkinson’s 
diseases. The contribution of mitochondria to the pathogenic mechanisms underlying 
these pathologies is not completely characterized. Finding new mitochondrial 
regulators is a major challenge, both for basic science and for translational medicine. 
The goal of this project is to find new regulators that control mitochondrial biogenesis 
and function and validate them in C2C12, a skeletal muscle cell line, with the final 
aim to gain further insights on the mechanisms by which mitochondria are involved in 
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pathophysiology. 
Since most of the pathologies associated with mitochondrial dysfunction are 
characterized by reduced density and function of these organelles, we decided to 
focus our attention on the isolation of new “positive” mitochondrial regulators; in 
other words factors capable of inducing mitochondrial function.  
In all the experiments reported in this thesis we decided to use a gain of function 
approach instead of a loss of function strategy. Based on current knowledge, it might 
be expected that reduced expression of a given “potential” regulator does not 
necessarily lead to a marked phenotype. In this regard, the muscle-specific 
overexpression of the co-activator PGC-1α (a well characterized mitochondrial 
regulators) in mice induces an impressive switch toward oxidative-type muscle fibers 
containing large amounts of mitochondria [170, 171]. On the other hand PGC-1α-/- 
null mice displayed normal numbers of these fibers, and although mitochondrial gene 
expression and activity were blunted, mitochondrial fractional volume was unchanged 
in one study and only slightly decreased in another [71, 72]. 	  	  
To define potential mitochondrial regulators we performed a preliminary high 
throughput screening in HEK 293 cells, a cell line that allow high transfection 
efficiency. Afterwards, we characterized the new mitochondrial factors in the mouse 
skeletal muscle cell line C2C12, that are enriched in mitochondria. A mitochondrial 
regulator should increase both the mitochondrial biogenesis and function; thus we 
developed some biochemical-functional assays to evaluate these effects. We analyzed 
the mitochondrial DNA content as a hallmark of mitochondrial biogenesis and the 
oxygen consumption rate, the expression level of OXPHOS proteins and the ATP 
amount as a hallmark of mitochondrial function.  
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3.	  Materials	  and	  Methods:	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3.1	  Cell	  Culture	  
3.1.1	  Cell	  Lines	  
We used the human epithelial kidney HEK293 cells (ATCC) and the murine skeletal 
muscle myoblasts C2C12 cells (ATCC). 
3.1.2	  Medium	  
Maintenance Medium: Both cell lines were grown using the Dulbecco's Modified 
Eagle's Medium from Sigma (DMEM, D5671) added of 10% Fetal Bovine Serum 
(Euroclone), 2mM L-Glutamine (Life Technology) and 100U/ml Penicillin and 
100ug/ml Streptomycin (both Life Technology).  
Transfection Medium: We used for both cell lines the Dulbecco's Modified Eagle's 
Medium from Sigma (DMEM, D5671) without any addition. 	  
3.2	  Expression	  Vectors	  
3.2.1	  pCDNA3	  
pCDNA3 empty vector (Open Biosystem) was used as negative control. A plasmid 
bearing the sequence encoding PGC-1α in the pCDNA3 vector (Open Biosystem) was 
used as positive control.  
3.2.2	  pCMV	  
This is the vector in which is cloned the cDNA coding for the green fluorescent 
protein (GFP), source Open Biosystem. We used this plasmid as a control of 
transfection degree.  
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3.2.3	  pCMV	  Sport	  6.1	  
This is the vector in which are cloned all the cDNAs coding for the 22 potential 
mitochondrial regulators. We bought all these plasmids already assembled with the 
different genes from Open Biosystem. All the genes coding for the different 
candidates are murine except for genes 2 and 22 that are human. 
 
3.3	  Reporter	  System	  
3.3.1	  Wild	  Type	  TFAM	  Reporter	  System	  (WT	  TFAM)	  
This reporter system has the luciferase expression under the control of the Tfam 
promoter. The promoter is composed of the region for the binding of NRF-1, Sp1 and 
NRF-2. We used this reporter system in the HTS experiment, but also to evaluate the 
Tfam activation by Zc3h10.  
3.3.2	  Mutated	  TFAM	  Reporter	  System	  (MUT	  TFAM)	  
This reporter system has the luciferase expression under the control of a mutated form 
of the Tfam promoter. The promoter is deleted of the NRF-1 binding site. We used 
this reporter system to evaluate the Tfam activation by Zc3h10. 
3.3.3	  pTKLUC	  Reporter	  System 
This reporter system has the luciferase expression under the control of the TK 
(thymidine kinase) promoter. We used this reporter system to sustain the hypothesis 
that exist a specific interaction between the Zc3h10 protein and the Tfam promoter 
and not with Zc3h10 protein and the backbone of the plasmid.	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3.3.4	  Zc3h10	  Reporter	  System	  
This reporter system was purchased by SwitchGear Genomics and has the luciferase 
expression under the control of the Zc3h10 promoter. The promoter region cloned 
comprehends 907 bases. We used this reporter system to evaluate some possible 
inducer of the Zc3h10 promoter activity. 	  
3.4	  Bioinformatic	  Analysis	  
3.4.1	  Biological	  process	  and	  molecular	  function	  classification	  
This classification was performed using the free Panther Software 
(www.pantherdb.org). The genes were inserted as Enter IDs and the software 
provided the classification according to GeneOntology. 
3.4.2	  BioGPS	  analysis	  
All the genes were inserted in BioGPS dataset (biogps.org) and their expression levels 
in the C2C12 cells and in the murine gastrocnemius were checked. 
3.4.3	  PubMed	  Analysis	  
All the proteins encoded by the different genes were checked using PubMed 
(www.ncbi.nlm.nih.gov), in order to understand which function they have and if they 
are already known as mitochondrial regulators.  	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3.5	  Transient	  Transfections	  
3.5.1	  HEK	  293	  Cotransfection	  in	  96	  well	  plates,	  “in-­‐plate	  transfection”	  
Materials: 
• 96 multi-well plate black (PerkinElmer) 
• C2C12 myoblasts (5000cell/well) 
• cDNA 80ng/well (pCDNA3, PGC-1α, candidates 1-22, and GFP) 
• reporter gene (WT Tfam-LUC) 20 ng/well 
• Fugene6 Transfection Reagent (Promega) 
• Transfection medium: DMEM Serum free, Sigma  
• Maintenance medium: DMEM Sigma + 1% pen-strep + 1% L-Gln + 10% fbs 
 
 
 
 
Protocol: 
• Add in each well with a matrix pipette 2ul of reporter gene from a solution 
concentrated 10ng/ul 
• Add in each well with a matrix pipette 4ul of each cDNAs from a solution 
concentrated 20ng/ul 
• Add in each well with a matrix pipette 3.5ul of DMEM serum free 
• Add in each well with a matrix pipette 0.5ul of Fugene 
• Centrifuge the plates for 2	  min	  a	  750	  rpm 
• Wait 20 minutes (the cDNA and Fugene have to form a complex) 
Quantities per well: 
- 100ul plated/well 
- cDNA: 80ng/well 
- reporter gene: 20ng/well 
- Fugene 1:5 
- cells: 5000 cells/well 
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• Add 90ul of cells concentrated 56000cell/ml.  
• Wait 40 minutes (the transfection has to happen) 
• Check the transfection efficiency 24h after transfection going to the 
fluorescent microscope and measuring how many green fluorescent cells you 
can see. (only for cells transcfected with GFP) 
3.5.2	  C2C12	  Myoblasts	  Transfection	  in	  96	  well	  plates	  
Materials: 
• 96 multi-well plate black (PerkinElmer) 
• C2C12 myoblasts (10000cell/well) 
• cDNA 125 ng/well (pCDNA3, PGC-1α, Zc3h10, and GFP) 
• Fugene6 Transfection Reagent (Promega) 
• Transfection medium: DMEM Serum free, Sigma  
• Maintenance medium: DMEM Sigma + 1% pen-strep + 1% L-Gln + 10% fbs 
	  	  	  
 
 
Protocol: 
• Add 189.5ul of DMEM serum free into a 2ml tubes 
• Add 4.25ul of each cDNAs from a solution concentrated 300ng/ul 
• Add 6.25ul of Fugene 
• Wait 20 minutes (the cDNA and Fugene have to form a complex) 
• Add 75ul of cells concentrated 1300000cell/ml.  
Quantities per well: 
- 100ul plated/well 
- cDNA: 125ng/well 
- Fugene 1:5 
- cells: 10000 cells/well 
Quantities per mix:(1 mix = 10 wells)  
- Final Volume: 1ml /mix  
- Transfection Volume: 275µl/mix 
- cDNA: 1250ng/mix 
- Fugene 1:5: 6.25ul 
- Cells: 100000 cells/mix 
- cell volume: 75ul 
- cell concentration: 1300000cell/ml 
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• Wait 40 minutes (the transfection has to happen) 
• Add 725ul of DMEM Sigma + 1% pen-strep + 1% L-Gln + 10% fbs 
• Plate 100ul each well. 
• Check the transfection efficiency 24h after transfection going to the 
fluorescent microscope and measuring how many green fluorescent cells you 
can see. (only for cells transcfected with GFP) 
3.5.3	  C2C12	  Myoblasts	  Transfection	  in	  24	  well	  plates	  
Materials: 
• 24 multi-well plate  
• C2C12 myoblasts (20000cell/well) 
• cDNA 700 ng/well (pCDNA3, PGC-1α, candidates 1-22, and GFP) 
• Fugene6 Transfection Reagent (Promega) 
• Transfection medium: DMEM Serum free, Sigma  
• Maintenance medium: DMEM Sigma + 1% pen-strep + 1% L-Gln + 10% fbs 
 
 
 
 
 
 
Protocol: 
• Add 482 ul of DMEM serum free into a 2ml tubes 
• Add 7.5 ul of each cDNAs from a solution concentrated 300ng/ul 
• Add 11.2 ul of Fugene 
Quantities per well: 
- 500 ulplated/well 
- cDNA: 700 ng/well 
- Fugene 1:5 
- cells: 20000 cells/well 
Quantities per mix:(1 mix = 3.25  wells)  
- Final Volume: 1,625 ml /mix  
- Transfection Volume: 679 µl/mix 
- cDNA: 2240 ng/mix 
- Fugene 1:5: 11.2 ul 
- Cells: 100000 cells/mix 
- cell volume: 178 ul 
	   47	  
• Wait 20 minutes (the cDNA and Fugene have to form a complex) 
• Add 178 ul of cells concentrated 560000 cell/ml.  
• Wait 40 minutes (the transfection has to happen) 
• Take the mix to the final volume with DMEM Sigma + 1% pen-strep + 1% L-
Gln + 10% fbs 
• Plate 500 ul in each well. 
• Check out the transfection efficiency 24h after transfection going to the 
fluorescent microscope and measuring how many green fluorescent cells you 
can see. (only for cells transcfected with GFP) 
3.5.4	  C2C12	  Myoblasts	  Transfection	  in	  6	  well	  plates	  
Materials: 
• 6 multi-wells plate  
• C2C12 myoblasts (500.000 cell/well) 
• cDNAs3.36 ug/well (pCDNA3, PGC-1α, Zc3h10, and GFP) 
• Fugene6 Transfection Reagent (Promega) 
• Transfection medium: DMEM Serum free, Sigma  
• Maintenance medium: DMEM Sigma + 1% pen-strep + 1% L-Gln + 10% fbs 
 
 
 
 
 
 
 
Quantities per well: 
- 2 ml plated/well 
- cDNA: 3.36 ug/well 
- Fugene 1:5 
- cells: 500000 cells/well 
Quantities per mix:(1 mix = 6.5wells)  
- Final Volume: 13 ml /mix  
- Transfection Volume: 1 ml/mix 
- cDNA: 21.84 ug/mix 
- Fugene 1:5: 109.2ul 
- Cells: 3500000 cells/mix 
- cell volume: 928ul 
- cell concentration: 3500000 cell/ml 
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Protocol: 
• Add 2.418 ml of DMEM serum free into a 50ml tubes 
• Add 73ul of each cDNAs from a solution concentrated 300ng/ul 
• Add 109.2ul of Fugene 
• Wait 20 minutes (the cDNA and Fugene have to form a complex) 
• Add 928 ul of cells concentrated 3500000 cell/ml.  
• Wait 40 minutes (the transfection has to happen) 
• Take the mix to the final volume with DMEM Sigma + 1% pen-strep + 1% L-
Gln + 10% fbs 
• Plate 2 ml in each well. 
• Check out the transfection efficiency 24h after transfection going to the 
fluorescent microscope and measuring how many green fluorescent cells you 
can see. (only for cells transcfected with GFP) 
3.5.5	  C2C12	  Myoblasts	  Cotransfection	  in	  96	  well	  plates	  
Materials: 
• 96 multi-well plate black (PerkinElmer) 
• C2C12 myoblasts (3000cell/well) 
• cDNA 132ng/well (pCDNA3, PGC-1α, Zc3h10, and GFP) 
• report system 66ng/well (WT Tfam-LUC, MUT Tfam-LUC, pTK-LUC or 
Zc3h10-LUC) 
• Lipofectamine 2000, Sigma 
• Transfection medium: DMEM Serum free, Sigma  
• Maintenance medium: DMEM Sigma + 1% pen-strep + 1% L-Gln + 10% fbs 
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Protocol: 
• Add 29.6ul of DMEM serum free into a 2ml tubes 
• Add 8.8ul of each cDNAsfrom a solution concentrated 150ng/ul 
• Add 6.6ul of the reporter system from a solution concentrated 100 ng/ul 
• Add 4ul of Lipofectamine 
• Wait 20 minutes (the DNA and Fugene have to form a complex) 
• Add 50ul of cells concentrated 600000cell/ml.  
• Wait 40 minutes (the transfection has to happen) 
• Add 900ul of DMEM Sigma + 1% pen-strep + 1% L-Gln + 10% fbs 
• Plate 100ul each well. 
• Check the transfection efficiency 24h after transfection going to the 
fluorescent microscope and measuring how many green fluorescent cells you 
can see. (only for cells transcfected with GFP) 
	  
3.6	  Mitochondrial	  activity	  evaluation	  (HTS	  validation)	  	  
The mitochondrial activity was analyzed 60 hours after cotransfection of 
HEK293cells in 96 multi-well plates. 
Materials: 
Quantities per well: 
- 100ul plated/well 
- cDNA: 132ng/well 
- reportersystem:66ng/well 
- Lipo: 5ul 
- cells: 3000 cells/well 
Quantities per mix:(1 mix = 10 wells)  
- Final Volume: 1ml /mix  
- Transfection Volume: 100µl/mix 
- cDNA: 1320ng/mix 
- reportersystem: 660 ng/mix 
- Lipo5ul 
- Cells: 100000 cells/mix 
- cell volume: 50ul 
- cell concentration: 600000cell/ml 
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• MitoTracker Red CM-H2Xros 
• PBS 1X 
• Hoechst 33258 
• H2O 
• EnVision (Perkin Elmer, Waltham, MA) 
Protocol: 
• Remove media from wells 
• Wash once cells with PBS 1X 
• Stained cell with 50 ul of a solution of MitoTracker Red CM-H2Xros 400nM 
in PBS 1X for 30 minutes at 37°C. 
• Remove the staining and wash once cells with PBS 1X 
• Read the fluorescence without any solution in the wells (dry cells) 
(EnVision protocol: Bottom Mirror: FITC Bottom 
Excitation filter: FITC 580nm 
Emission filter: FITC 620nm) 
• Stained cell with 50 ul of a solution of Hoechst 3325 diluited1:1000 in H2O 
for 3 minutes at RT. 
• Remove the staining and wash once cells with PBS 1X 
• Read the fluorescence without any solution in the wells (dry cells) 
(EnVision protocol: Bottom Mirror: DAPI Bottom 
Excitation filter: FITC 320nm 
Emission filter: FITC 460nm) 
The mitochondrial activity values obtained by MitoTracker Red CM-H2Xros staining 
were than divided for the number of cells measured by Hoechst 3325 staining. 
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3.7	  quantitative	  Real	  Time	  PCR	  (qRT-­‐PCR)	  
3.7.1	  mtDNA	  
Total DNA from C2C12 myoblasts was extracted 60 hours after transfection and 
purified with NucleoSpin® Tissue extraction kit (Macherey-Nagel, Milano, Italia) 
and quantitated with Nanodrop (Thermo Scientific, Wilmington, DE). Each sample 
was diluted at 5 ng/ul. Specific DNA sequences were amplified and quantitated by 
real time PCR, using iScriptTM One Step RT-PCR for Probes (Bio-Rad, Milano, 
Italia), following the manufacturer’s instructions. Experiments were performed in 
triplicate and repeated at least twice with different cell preparations. Calculate the 
mtDNA levels comparing the target gene (Mitochondrial) values with the 
houskeeping gene (Nuclear) values. The qRT-PCR protocol is composed of 40 cycles 
of amplifications each consisting of a denaturation step at 95° C for 15 seconds and 
an annealing/extension step at 60° C for 60 seconds. The oligonucleotides used for 
real-time PCR were synthesized by Eurofin MWG Operon (Ebersberg, Germany) and 
were: 
 
 
 
 
3.7.2	  mRNA	  
Total RNA from murine skeletal muscle was extracted with TRIzol Reagent® 
(Invitrogen) and purified with commercial kit (Macherey-Nagel, Milano, Italia) and 
quantitated with Nanodrop (Thermo Scientific, Wilmington, DE). Specific mRNA 
fwd AGATGCAGCAGATCCGCAT
m36B4 rev GTTCTTGCCCATCAGCACC
probe CGCTCCGAGGGAAGGCCG
fwd TGGTGAACTACGACTGCT
m mtCOX II rev CTGGGATGGCATCAGTTT
probe TGGCAGAACGACTCGGTTATCAACT
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was amplified and quantitated by real time PCR, using One Step for probes kit (Bio-
Rad, Milano, Italia) following the manufacturer’s instructions. Data were normalized 
to 36B4 mRNA and quantitated setting up a standard curve. 
Experiments were performed in triplicate. Primers for real-time PCRs were designed 
with IDT software available on line. The qRT-PCR protocol is composed of 10 min at 
50°C for reverse transcription, 40 cycles of amplifications each consisting of a 
denaturation step at 95° C for 10 seconds and an annealing/extension step at 60° C for 
30 seconds. The oligonucleotides used for qRT-PCR were synthesized by 
EurofinMWG Operon (Ebersberg, Germany) and were: 
 	  	  	  
3.8	  Oxygen	  Consumption	  Evaluation 
Materials: 
• Trypsin 
• Oxygen Consumption Buffer, 50 ml total PBS with: 
- 25 mM D-Glucose 
- 1 mM Na pyruvate 
- Fatty acid free BSA 2% w/v (g/100ml) 
• Oligomycin 2.5 mM 
• CCCP 10 mM 
Protocol: 
• Remove media from wells 
fwd AGATGCAGCAGATCCGCAT
rev GTTCTTGCCCATCAGCACC
fwd TGGTGAACTACGACTGCT
rev CTGGGATGGCATCAGTTT
fwd CATTTGATGCACTGACAGATGGA(
rev GTCAGGCATGGAGGAAGGAC(
fwd CACCCAGATGCAAAACTTTCAG
rev CTGCTCTTTATACTTGCTCACAG
fwd CCTACGAATGTAACTTGGCTCC
rev CTGCTCCAGAAGTACCTCATTG
m36B4
m mtCOX II
mPgc-1α
mTfam 
mZc3h10
fwd AGATGCAGCAGATCCGCAT
rev GTTCTTGCCCATCAGCACC
fwd TGGTGAACTACGACTGCT
rev CTGGGATGGCATCAGTTT
fwd CATTTGATGCACTGACAGATGGA(
rev GTCAGGCATGGAGGAAGGAC(
C CCCAGATGCAA ACTTTCAG
CT C TATAC TGCTCACAG
CC ACGA TG ACTTG CC
CTGCTCC GAAGTA CTCA TG
m36B4
m mtCOX II
mPgc-1α
Tfam 
mZc3h10
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• Detach cells with Trypsin 
• Centrifuge cells at 2000 rpm for 3 min 
• Discard supernatant 
• Resuspend cells in 1 ml of oxygen consumption buffer 
• Evaluate the basal level of oxygen consumption 
• To measure the uncoupled respiration, treat cells with oligomycin 2.5 uM 
• To measure the maximal respiration, treat cells with CCCP 3.75 uM 
• Remove the sample from the chamber and use 200 ul for normalizing values 
with the proteins quantification 
Centrifuge remaining cells for WB analysis 
 
3.9	  Measurement	  of	  promoter	  activity	  
3.9.1	  Measurement	  of	  Tfam	  promoter	  activity	  and	  pTK-­‐LUC	  
The Tfam promoter activity or the pTK-LUC was analyzed 24 hours after transfection 
of C2C12 myoblasts in 96 multi-well plates. 
Materials: 
• Britelite	  (Perkin	  Elmer) 
• EnVision (Perkin Elmer, Waltham, MA) 
Protocol: 
• Remove the medium from each well 
• Add 50ul of fresh Britelite prepared according the company’s instruction 
• Wait 2 minutes and read the luminescence with the EnVision device 	  
	   54	  
3.9.2Measurement	  of	  Zc3h10	  promoter	  activity	  
Materials: 
• Renilla	  (Promega) 
• EnVision (Perkin Elmer, Waltham, MA) 
Protocol: 
• Remove the medium from each well 
• Wash cells with 50 ul of PBS 
• Add 20ul of Renilla Luciferase assay Lysis buffer prepared according to 
manufacturer’s instruction 
• Wait 15 minutes and read the luminescence with the EnVision device 	  
3.10	  Protein	  Extraction	  and	  Dosage	  	  
Material:  
• C2C12 myoblasts 
• 96 multi-well plates  
• RIPA buffer 
• BSA 2 mg/ml 
• KIT BCA Kit (Pierce)  
RIPA Buffer preparation: 
 TrisHCl pH 7,4 50mM 
 NP-40 1% 
 Na-desossicolate 0,25% 
 NaCl 150 mM 
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 EDTA 1mM 
 Protease Inhibitors, 10ul/ml (Sigma) 
 H2O to reach the desired volume 
Proctocol: 
• Prepare in a 96 wells plate a standard curve in duplicate following the table: 
curvepoints Pointsconcentration 
mg/ml 
ulfrom 2mg/ml 
BSA stock  
ul H2O ulLysis 
Buffer 
A 1 5 ul x 5 ul 
B 0,75 3,75 1,25 5 ul 
C 0,5 2,5 2,5 5 ul 
D 0,25 1,25 3,75 5 ul 
E 0,125 0,62 4,38 5 ul 
F 0 x 5 ul 5 ul 
 
    
• Centrifuge cells and remove the supernatant 
• Add 200ul RIPA buffer to lysate cells 
• If some gelatinous conglomerate is present, centrifuge for 3 min at 14000 rpm 
and keep the supernatant  
• Aliquote5 ul of the supernatant of each samples in the wells 
• Prepare the BCA reagent: 50 Reagent A : 1 Reagent B 
• Add 200ul of BCA Reagent in each well 
• Incubate 30 min a 37°C 
• Read the absorbance at 550 nm  
• Calculate the total mg of protein for each sample 
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3.11	  Western	  Blot	  
The proteins used for this analyses were collected from the same sample used for the 
Oxygen consumption, after this measurement 
3.11.1	  OXPHOS	  WB	  
Solutions preparation: 
1. SDS-sample buffer 2X: 
 20% Glycerol 
 4% SDS 
 100 mMTris pH 6.8 
 0.002% BBF 
2. Running buffer 10X: 
 144g Glycine 
 30g Tris 
 Bring to 8.4 pH 
 10g of SDS 
 Add water to reach 1L 
3. Running Buffer 1X: 
 100ml of Running Buffer 10X 
 900 ml of H2O 
4. CAPS buffer: 
 4.52g CAPS (Sigma) 
 Add 1.6L of H2O 
 Bring to pH 11 
 Add H2O to reach 2L volume 
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5. PBS: 
 8g NaCl 
 0.2g KCl 
 1.44g Na2HPO4 
 0.24g KH2PO4 
 Add H2O to reach 1L volume 
Material: 
• SDS – sample buffer 2X 
• Running Bffer 1X 
• CAPS Buffer 
• MitoProfile® Total OXPHOS Rodent WB Antibody Cocktail (ab110413) 
• mouse anti beta actin Antibody (Sigma) 
• Secondary anti-mouse Ab conjugated with horseradish peroxidase 
• PBS 1X 
• Tween-20 
• Milk powder 
• ECL western blot substrate (Pierce) 
Protocol: 
• Load 10 ug of samples proteins (previously resuspended 1ug/ul in SDS – 
sample buffer 2X, in order to lysate cells) in each well 
• Separate proteins on a 10 wells Tris-Glycine 12.5 % PAA gel at 110 V in the 
Running Buffer 1X 
• Soak gel and a PVDF membrane in CAPS buffer for 30 min 
• Transfer to the PVDF membrane in CAPS buffer for 2 hours 
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• Overnight block in 5% milk/PBS 4° C 
• Incubate blot with MitoScienceAb cocktail diluted 1:250 in 1% milk/PBS for 
2 hours or with the anti beta actin antibody diluted 1:1000 in 1% milk/PBS for 
1 hour 
•  Wash 3 times in PBS/0.05% tween-20 for 5 min 
• Incubate blot with secondary anti-mouse Ab diluted 1:5000 in 1% milk/PBS 
for 2 hours 
• Wash 3 times in PBS/0.05% tween-20 for 5 min 
• Develop with ECL western blot substrate	  
3.11.2	  Zc3h10	  WB	  
Solutions preparation: 
1. SDS-sample buffer 2X: 
 20% Glycerol 
 4% SDS 
 100 mMTris pH 6.8 
 0.002% BBF 
2. Running buffer 10X: 
 144g Glycine 
 30g Tris 
 Bring to 8.4 pH 
 10g of SDS 
 Add water to reach 1L 
3. Running Buffer 1X: 
 100ml of Running Buffer 10X 
 900 ml of H2O 
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4. Transfer buffer 10X: 
 288g Glycine  
 60.4 Tris Base 
 Add H2O to reach 1L volume 
5. Transfer Buffer 1X: 
 100ml of Transfer Buffer 10X 
 200ml of Methanol 
 Add H20 to reach 1L volume 
6. PBS: 
 8g NaCl 
 0.2g KCl 
 1.44g Na2HPO4 
 0.24g KH2PO4 
 Add H2O to reach 1L volume 
7. TBS-T (1L): 
 50mM Tris 
 150mM NaCl 
 Adjust pH with HCl to pH 7.6 
 1ml of Tween 20 
Material: 
• SDS – sample buffer 2X 
• ZC3H10 primary antibodie (AVIVA) 
• mouse anti beta actin Antibody (Sigma) 
• Secondary anti-mouse Ab conjugated with horseradish peroxidase (Sigma) 
• Secondary anti-rabbit Ab conjugated with horseradish peroxidase (Sigma) 
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• PBS 1X 
• PBS-T 0,05 % 
• BSA 
• TBS-T 0,1 % 
• ECL western blot substrate (Pierce) 
Protocol: 
• Load 25 ug of samples proteins (previously resuspended 1ug/ul in SDS – 
sample buffer 2X) in each well 
• Separate proteins on a 10 wells Tris-Glycine 12.5 % PAA gel at 110 V in the 
Running Buffer 1X 
• Transfer to the NitroCellulose membrane in transfer buffer for 1 hour and half 
at 350 mA 
• Block in 5% BSA/PBS-T at RT for 2 hs 
• Incubate blot with ZC3H10 antibody diluted 1:1000 in 3% BSA/TBS-T for 
O/N 
• Wash 3 times in TBS-T 0,1% for 5 min 3 times 
• Incubate blot with secondary anti-rabbit Ab diluted 1:50000 in 3% BSA/TBS-
T for 1 hour 
• Wash 3 times in TBS-T 0,1% for 5 min 3 times 
Develop with ECL western blot substrate 
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3.12	  Evaluation	  of	  ATP	  Production	  
The ATP production was analyzed 60 hours after transfection of C2C12 myoblasts in 
96 multi-well plates. 
Solutions preparation: 
1. Oligomycin 5 uM in serum free DMEM media 
2. DMSO 5 uM in serum free DMEM media 
3. Standard curve solutions: ATP 50, 5, 0.5, 0.05, 0.005, 0.0005 uM in PBS 
4. ATP buffer solution 
Protocol: 
• Treat samples with the solutions 1 or 2 at 37° C for 24 hours (100 uL/well) 
After 24 hours: 
• Keep the PBS 1X at RT 
• Remove the medium from each well 
• Aliquote 50 uL of standard curve solutions in the respective wells 
• Aliquote 50 uL of PBS in samples wells 
• Aliquote 50 uL of solution 4 in each well 
• Shake the 96 well plate for 2 minutes using an orbital shaker 
• Measure the luminescence (EnVision, PerkinElmer) 
 
To calculate the cytosol ATP production, subtract the luminescence signal obtained 
from the oligomycin treated samples to the signal obtained from the respective 
vehicle treated samples. 
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3.13	  Evaluation	  of	  ROS	  production	  
The ROS production was analyzed 60 hours after transfection of C2C12 myoblasts in 
96 multi-well plates. 
Solutions preparation: 
1. Solution H2O2 10mM in PBS 
. 2ul H2O20.9M (H2O2 3% bought in pharmacy) 
. 178ul PBS 1X at 37°C 
2. Solution H2DCFDA 10mM 
Add 8.6ul of DMSO to the lyophilized probe (Invitrogen cod. c6827) 
3. Solution H2O2 25uM and H2DCFDA 5uM in PBS: 
. 3ul H2DCFDA 10mM 
. 15ul H2O2 10mM 
. 5982ul PBS 1X at 37°C 
4. Solution H2DCFDA 5uM in PBS: 
. 3ul H2DCFDA 10mM 
. 5997 PBS 1X at 37°C 
5. Blank solution DMSO 0.05%: 
. 3ul DMSO 
. 5997ul PBS 1X at 37°C 
6. Blank with H2O2solution (H2O2 25uM in PBS without probe) 
. 1.25ul H2O2 10mM 
. 499ul PBS 1X at 37°C 
Protocol: 
• Warm the PBS 1X at 37°C 
• Prepared all the solution 
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• Remove the medium from each well 
• Treat each well with the appropriate solution 3-6 
• Leave for 30 minutes at 37°C 
• Remove the treatment solutions from each well 
• Wash once with pre-warmed PBS 1X 
• Read the fluorescence without any solution in the wells (dry cells) 
(EnVision protocol: Bottom Mirror: FITC Bottom 
Excitation filter: FITC 485nm 
Emission filter: FITC 535nm) 
• Add 30ul of Ripa Buffer in each well 
• Vortex the wells  
• Protein Dosage using the BCA kit (cod. 23227 Pierce BCA Protein Assay Kit) 
We decided to normalize the Ros detection data dividing them by the number 
of proteins. 
 
3.14	  Evaluation	  of	  membrane	  potential	  	  
The mitochondrial membrane potential was analyzed 60 hours after transfection of 
C2C12 myoblasts in 96 multi-well plates. 
Solutions preparation: 
1. Solution JC-1 3uM in PBS 
. 2.34ul JC-1 7.7mM  
. 5998ul PBS 1X at 37°C 
2. Solution JC-1 3uM and CCCP 10uM 
. 1ul CCCP 10mM in DMSO 
	   64	  
. 999ul solution 1 
3. Blank solution (for JC-1): 
. 2.34ul DMSO 
. 5998ul PBS 1X at 37°C 
4. Blanksolution (for CCCP): 
. 1ul DMSO 
. 999ul solution3 
Protocol: 
• Warm the PBS 1X at 37°C 
• Prepared all the solution 
• Remove the medium from each well 
• Treat each well with the appropriate solution 1-4 
• Leave for 30 minutes at 37°C 
• Remove the treatment solutions from each well 
• Wash once with pre-warmed PBS 1X 
• Read the fluorescence without any solution in the wells (dry cells) 
EnVision protocols:  
GREEN MONOMERS 
Bottom Mirror: FITC Bottom 
Excitation filter: FITC 485nm 
Emission filter: FITC 535nm 
RED J-AGGREGATE 
Bottom Mirror: FITC Bottom     
Excitation filter: FITC 485nm                                       
Emission filter: FITC 600nm
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• Add 30ul of Ripa Buffer in each well 
• Vortex the wells  
• Protein Dosage using the BCA kit (cod. 23227 Pierce BCA Protein Assay Kit) 
To calculate the mitochondrial membrane depolarization you have to calculate the JC-
1 ratio, you have to divide the red J-Aggregates value for the green monomer value.  
We decided to normalize the depolarization data dividing the JC-1 ratio values by the 
number of proteins. 
 
3.15	  Zc3h10	  expression	  levels	  in	  different	  mice	  organs	  	  
C57Bl/6J mice were purchased from Charles River Laboratories, Calco, Italy. Four 
male mice at 10 weeks of age were sacrificed and the different organs were collected. 
All animal studies were approved by the local ethical committee and followed the 
Italian and European Community legislation. 
The tissues were kept in nitrogen tillthe mRNA was extracted as explained before. 	  3.16	  Statistical	  analysis	  
Statistical analyses were performed with Student’s t test or one-way ANOVA 
followed by Dunnett’s Post Test when needed using GraphPadPrism version 5.0 for 
Macintosh (GraphPad, San Diego, California). 
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4.	  Preliminary	  Results:	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4.1	  High	  Throughput	  Screening	  
Since all factors known to influence mitochondrial number or OXPHOS appear to 
modulate the expression of Tfam, evaluation of its promoter activity can be used as a 
screening system to identify genes and genetic pathways that regulate mitochondrial 
biogenesis. To aid functional annotation of the genome, the Genomics Institute of the 
Novartis Research Foundation (GNF) has developed technology to assess the role of 
genes in a high-throughput manner in cell-based phenotypic assays. Specifically, 
GNF has assembled genome-wide cDNA and siRNA collections, arrayed them in 
384-well format (1 gene/well), developed robotics/automation and procedures to 
manipulate, transfect cells, and evaluate gene activity in transfected cells in a high-
throughput screen (HTS) fashion (Fig. 4.1.1). This technology has been used to 
discover new oncogenes, transcriptional co-activators that regulate metabolism, 
modulators of apoptosis, p53, Wnt signaling, etc.[172-177]. 
 
 
 
 
 
 
 
 
Figure 4.1.1: Scheme of the Tfam-Luc transfection used in the screen. 
 
 
Pre-arrayed 384 well cDNAmatrix  
Cells,  
reporter gene (Tfam-LUC), 
transfection reagent) 
HTS transfection 
Incubate plates 
Assay detection 
by Luminescence 
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In collaboration with the GNF we applied this technology was to identify genes that 
modulate mitochondrial number and function. To this end two cDNA libraries, which 
account for 70% of known genes, were overexpressed in mammalian expression 
vectors by transient transfection in HEK 293 cells. One of these libraries contains 
16,000 fully sequenced cDNAs (MGCv2, mouse and human), while the other one 
includes 11,000 5’ and 3’ sequenced cDNAs (Origene, mouse and human). These 
collections have been arrayed onto 384-well plates for functional screening, with a 
single cDNA spotted per well to facilitate deconvolution of results. Individual cDNAs 
were co-transfected with a luciferase reporter to measure the activity of mitochondrial 
transcription factor A (Tfam; Fig. 4.1.2).  
 
 
 
Figure 4.1.2: Scheme of the Tfam-Luc reporter system. 
 
Since all factors known to influence mitochondrial number or oxidative 
phosphorylation such as PGC-1α, NAD+-dependent histone/protein deacetylases such 
as sirtuins and in particular SIRT1, NRF1 and p160 myb binding protein appear to 
modulate Tfam expression levels, evaluation of Tfam promoter activity can serve as a 
marker to identify genetic pathways that regulate mitochondrial biogenesis. Pilot 
experiments with this reporter performed in screening mode (384-well, robotic 
manipulations) indicate that the signal to noise ratio is robust and appropriate for HTS 
(Fig. 4.1.3).  
 
 
	   	  	   	  NRF1 NRF2 Sp1 Luciferase 
Tfam promoter 
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Figure 4.1.3: validation of Tfam promoter in HEK 293 cells. PGC-1α and SIRT1 were used 
as positive control and p160 myb binding protein as negative. Data are presented as relative 
light unit (RLU). Statistical analysis was performed using one way ANOVA followed by 
Tukey post test, **P<0.001. 
 
Libraries were screened in duplicate and data statistically evaluated to select hits. 
cDNA was considered a hit if it regulated Tfam expression as much as positive 
known regulators of mitochondrial functions such as PGC-1α (positive, [63]) and 
p160 myb binding protein (negative, [178]). All hits were checked against GNF’s 
genomic screening database to exclude genes that induce Tfam activity in a not 
specific manner. The genomic HTS yielded 441 clones able to induce and 300 clones 
able to reduce Tfam promoter activity (Fig. 4.1.4 A and B).  
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Hits 
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Figure 4.1.4: graphical representation of the mitochondrial screen data analysis. A) Data plot 
in a Log2 based scale. The distribution of the data shows the positive and the negative hits 
(blue circle) at the upper and the lower bound of the X axis. B) This graph shows the score 
ofpositive (PGC-1α) and negative (p160 myb) controls in the screen determining the cut off 
to choose the hits. 	  
	  
4.2	  FACS	  Analysis	  
As already mentioned, we focused our attention only on the 441 positive candidates, 
as our final aim is to discover new positive mitochondrial regulators. All hits from the 
cDNA screen were confirmed in HEK 293 cells by flow cytometry analyses of cells 
transfected with a single cDNA and stained with Mitotracker® Green and 
Mitotracker® CM-H2X-ROS as markers for mitochondrial density and function, 
respectively. Notably, by applying these screening assays, we were able to identify 
factors already known to promote mitochondrial biogenesis like CREB (cAMP 
response element binding protein [179]) among the positive hits.  
Starting from 441 genes, 131 positive candidates were confirmed to modulate 
mitochondrial density and activity in HEK293 cells. 	   	  	  	  
Sirt1 
PGC-1α p160myb 	  
B) 
	  	   71	  
	  
	  
	  
	  
	  
	  
5.	  Results:	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5.1	  Bioinformatic	  Analysis	  
In order to better investigate 131 genes, we classified them according to their 
biological and molecular function (GeneOntology classification). By using	  Panther	  software (www.pantherbd.org) we	   were	   able	   to classify 126 candidates, so we 
decided to exclude the five missing genes from the analysis, as either they did not 
have aliases or they were not recognized by the software.  
	  
5.1.1	  Biological	  process	  classification	  
By classifying the 126 candidates according to their biological function, we found that 
the 40% of the encoded proteins are involved in cellular and metabolic processes (Fig. 
5.1.1 and Table 5.1). Hence, we decided to classify these two components in more 
depth. The genes classified	  as	  belonging	  to metabolic processes are mainly involved 
in nucleic acid metabolic processes or in protein metabolic processes (Fig.5.1.1 B and 
Table 5.2). On the other hand, the genes that	  according	  to	  GO	  classification	  belong	  to cellular processes are mainly involved in cell cycle or in cell communication (Fig. 
5.1.1 C and Table 5.3). 
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Figure 5.1.1: The 126 genes were classified according to GeneOntology biological processes 
(A), metabolic processes (B) and Cellular processes (C) using www.pantherdb.org. 
 
Table 5.1: Biological process classification. 
 
Table 5.2: Metabolic process classification. 
 
 
BIOLOGICAL PROCESSES NR. OF GENES % 
cell communication (GO:0007154) 30 9.9% 
cellular process (GO:0009987) 47 15.5% 
localization (GO:0051179) 2 0.7% 
transport (GO:0006810) 20 6.6% 
cellular component organization (GO:0016043) 8 2.6% 
apoptosis (GO:0006915) 9 3.0% 
system process (GO:0003008) 18 5.9% 
reproduction (GO:0000003) 6 2.0% 
response to stimulus (GO:0050896) 14 4.6% 
developmental process (GO:0032502) 29 9.5% 
generation of precursor metabolites and energy (GO:0006091) 3 1.0% 
metabolic process (GO:0008152) 73 24.0% 
cell cycle (GO:0007049) 23 7.6% 
immune system process (GO:0002376) 18 5.9% 
cell adhesion (GO:0007155) 4 1.3% 
METABOLIC PROCESSES NR. OF GENES % 
nucleobase, nucleoside, nucleotide and nucleic acid metabolic 
process (GO:0006139) 40 45.5% 
lipid metabolic process (GO:0006629) 9 10.2% 
cellular amino acid and derivative metabolic process 
(GO:0006519) 6 6.8% 
protein metabolic process (GO:0019538) 26 29.5% 
carbohydrate metabolic process (GO:0005975) 7 8.0% 
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CELLULAR PROCESSES NR. OF GENES % 
cell motion (GO:0006928) 6 8.2% 
cell cycle (GO:0007049) 23 31.5% 
chromosome segregation (GO:0007059) 2 2.7% 
cell adhesion (GO:0007155) 4 5.5% 
cell communication (GO:0007154) 30 41.1% 
cellular component organization (GO:0016043) 8 11.0% 
Table 5.3: Cellular classification. 	  
5.1.2	  Molecular	  function	  classification	  
Analysis of the 126 genes by their molecular function revealed that the	  classes	  that	  describe	  a	  large	  fraction	  of	  the	  genes	  under	  investigations	  are binding (35%) and 
catalytic activity (33%) (Fig.5.1.2 A and Table 5.4). In addition, genes involved in 
binding are mainly nucleic acid binding proteins (74%) (Fig.5.1.2 B and Table 5.5), 
while those involved in catalytic activity are mainly involved either in hydrolase 
activity (31%) or in transferase activity (23%) (Fig. 5.1.2 C and Table 5.6). 
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Figure 5.1.2: The 126 genes were classified according to GeneOntologymolecular functions 
(A), Binding type (B) and Catalitic activity (C) using the panther software 
(www.pantherdb.org). 
 
MOLECULAR FUNCTIONS NR. OF GENES % 
ion channel activity (GO:0005216) 2 1.3% 
transporter activity (GO:0005215) 5 3.3% 
translation regulator activity (GO:0045182) 1 0.7% 
transcription regulator activity (GO:0030528) 18 11.8% 
enzyme regulator activity (GO:0030234) 9 5.9% 
catalytic activity (GO:0003824) 49 32.2% 
motor activity (GO:0003774) 1 0.7% 
receptor activity (GO:0004872) 7 4.6% 
antioxidant activity (GO:0016209) 1 0.7% 
structural molecule activity (GO:0005198) 5 3.3% 
binding (GO:0005488) 54 35.5% 
Table 5.4: Molecular function classification. 
 
Table 5.5: Binding classification. 	  	  	  	  	  
BINDING NR. OF GENES % 
nucleic acid binding (GO:0003676) 37 58.7% 
calcium ion binding (GO:0005509) 1 1.6% 
chromatin binding (GO:0003682) 4 6.3% 
protein binding (GO:0005515) 21 33.3% 
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Table 5.6: Catalytic classification. 
	  
5.1.3	  BioGPS	  and	  PubMed	  analysis	  
To further narrow down the number of positive hits to be included in future 
experiments we established some selection criteria. We chose hits that are involved in 
one or more key cell function according to the bioinformatic classification reported 
above. Moreover, we verified the expression profile of the candidate genes in 
HEK293 cells, in C2C12 cells and in the mouse gastrocnemius, by interrogating the 
BioGPS database. Then we assigned priority to those genes for which no links with 
mitochondria are known yet, by performing a research in literature through PubMed. 
By applying these selection criteria we chose 22 candidates; 3 belonging to the 
category  “catalytic activity”, 4 to the category “signal transduction”, 11 to the 
category “transcription processes”, 4 genes encoding for structural proteins and 1 
whose function has not been annotated yet. 
 
 	  	  
CATALYTIC ACTIVITY NR. OF GENES % 
transferase activity (GO:0016740) 12 21.8% 
ligase activity (GO:0016874) 2 3.6% 
deaminase activity (GO:0019239) 2 3.6% 
helicase activity (GO:0004386) 1 1.8% 
hydrolase activity (GO:0016787) 18 32.7% 
RNA splicing factor activity, transesterification 
mechanism (GO:0031202) 6 10.9% 
lyase activity (GO:0016829) 4 7.3% 
oxidoreductase activity (GO:0016491) 8 14.5% 
isomerase activity (GO:0016853) 2 3.6% 
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5.2	   HTS	   validation:	   evaluation	   of	   mitochondrial	   activity	   in	  
HEK	  293	  cell	  
In order to validate the HTS for the selected candidates, the 22 cDNAs were 
transiently transfected in HEK293 cells and their ability to increase the mitochondrial 
activity was assessed 60 h after transfection using the MitoTracker® CM-H2X-ROS 
dye. We selected this time point to allow transcription and translation of the 
transfected cDNAs and activation of the mitochondrial machinery. This was an “in-
plate” staining instead of flow cytometry-based assay; however this method displays 
advantages compared with flow cytometry, used in the first screen. The fluorescence 
relative to mitochondrial activity is detected in live cells directly in the wells with no 
need of trypsin to allow cells to detach from the well. The latter is a step required in 
flow cytometry that can alter cell morphology and activities. To evaluate the 
transfection efficiency we transfected the Green Fluorescent Protein (GFP) and the 
fluorescence was checked by microscope before performing the experiment. The cell-
permeant MitoTracker®CM-H2X-ROS probe contains a mildly thiol-reactive 
chloromethyl moiety for labeling mitochondria, the probe passively diffuse across the 
plasma membrane and accumulate in active mitochondria thus the fluorescence is a 
quantitative measure of the mitochondrial activity. As shown in Fig. 5.2.1, all the 
candidates were able to induce the mitochondrial activity with a higher or equal 
power compared to that of PGC-1α, confirming the data obtained with the previous 
screening performed in a high throughput format. 
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Figure 5.2.1: mitochondrial activity. HEK 293 cells transfected with the empty vector were 
used as control (CTRL), PGC-1α was used as positive control. Data were normalized against 
cell number and expressed setting at 1 the signal measured in CTRL samples. Statistical 
analysis was performed using t-test, ***P<0.0001, *vs CTRL. 
 
 
5.3	  Validation	  of	  the	  22	  genes	  in	  C2C12	  myoblasts	  
Skeletal muscle is one of the tissues with the strongest levels of dependence on 
mitochondrial function in regulating the oxidative metabolism, as shown by the 
severe impacts of mitochondrial diseases on muscle performance in patients [180]. 
Thus, skeletal muscle is an attractive tissue for analyzing in depth the regulation of 
mitochondrial biogenesis and function. By this means, we decided to characterize the 
22 candidates identified in C2C12 cell line, a mouse skeletal muscle cell line.  We 
used C2C12 myoblasts, since they are very well characterized and easily to manage 
and to transfect. In addition, in literature they are commonly used for studies dealing 
with the energetic metabolism. To evaluate the transfection efficiency we transfected 
the GFP and the fluorescence was detected by microscope before performing each 
single experiment.  	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5.3.1	  Evaluation	  of	  the	  mitochondrial	  biogenesis	  
Taking into consideration the previous results and what is reported in literature, we 
decided to investigate if the overexpression of the 22 candidates in C2C12 cells could 
lead to an increase in the mitochondrial DNA copy number [4, 93, 110, 181]. In fact, 
one of the hallmarks of mitochondrial biogenesis is the increase of mitochondrial 
DNA content. The 22 hits were individually transfected in C2C12 and after 60 hours 
total DNA (nuclear and mitochondrial) was extracted. We selected this time point to 
allow transcription and translation of the transfected cDNAs and to give them enough 
time to regulate the mitochondrial machinery. The mitochondrial DNA content was 
evaluated as the ratio between the amount of a mitochondrial encoded gene 
(cytochrome c oxidase subunit II, COXII) and the amount of a nuclear encoded gene 
(ribosomal protein large P0, Rplp0 or 36B4). The data were obtained using 
quantitative real-time polymerase chain reaction (qRT-PCR). As shown in Fig. 5.3.1, 
all the candidates increased the mitochondrial DNA content at the same or higher 
levels of those found in cells overexpressing PGC-1α, a very well known 
mitochondrial regulator [63].  
 
 
 
 
 
 
Figure 5.3.1: mtDNA quantification. C2C12 myoblasts were transfected with the empty 
vector (CTRL), with PGC-1α and all the22 cDNAs. Sixty hours after transfection total DNA 
was extracted from cells. The mtDNA was measured by qRT-PCR and expressed as the ratio 
between the amount of a mitochondrial gene (COXII) and a nuclear gene (36B4). The data 
were expressed setting at 1 the ratio found in cells transfected with the empty vector. 
Statistical analysis was performed using t-test, *P<0.05, **P<0.01, ***P<0.0001, *vs CTRL. 
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5.3.2	  Evaluation	  of	  the	  oxygen	  consumption	  rate	  
A potential mitochondrial regulator should increase not only the mtDNA copy 
number, but also the mitochondrial function. A functional approach to estimate the 
mitochondrial activity is the evaluation of the respiration, measured as nanomoles of 
oxygen consumed per minute. Whole C2C12 myoblasts individually transfected with 
the 22 genes, 60 hours after transfection, were measured for the basal oxygen 
consumption rate by using a Clark electrode-based oxygraph. As shown in Fig. 5.3.2, 
the overexpression of 13 out of the 22 candidates enhanced the basal respiration rate. 
In particular, overexpression of candidate 9, 10, 19 and 22 induced the respiration by 
1.7 times compared to the control. It is worth to notice that PGC-1α, our positive 
control, increased the respiration of 1.5 times, as already reported by other groups 
[63]. 
 
 
 
 
 
 
Figure 5.3.2: Oxygen Consumption. C2C12 myoblasts were transfected with the empty vector 
(CTRL), with PGC-1α and all the22 cDNAs. At 60 hours after transfection the cells were 
detached from the plates and transferred to a chamber for measurement of oxygen 
consumption. All data were normalized by protein content and were expressed setting at 1 the 
respiration rate measured in cells transfected with empty vector. Statistical analysis was 
performed using t-test, *P<0.05, **P<0.01, ***P<0.0001, *vs CTRL. 
 	  In	  the	  experimental	  conditions	  used,	  we	  observed	  that	  the	  overexpression	  of	  all	  22	   candidates	   induced	   a	   significant	   increase	   of	   mtDNA,	   suggesting	   a	   positive	  effect	   on	   mitochondrial	   biogenesis.	   Nonetheless	   only	   4	   of	   them	   were	   able	   to	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increase	   the	   basal	   respiration	   rate,	   index	   of	   enhanced	   oxidative	   function.	   All	  together	   these	   data	   indicate	   that	   not	   always	   an	   increase	   mitochondrial	   DNA	  couples	  with	  higher	  oxidative	  capacity	  in	  basal	  conditions.	  	  	  
At this point, we decided to focus our attention on only one candidate gene to deeply 
characterize its involvement in mitochondrial function. As shown in Fig. 5.3.3, the 
scatter plot revealed a cluster of four hits able to induce either mitochondrial DNA 
content and the oxygen consumption at level similar or higher than the known 
mitochondrial regulator PGC-1α. Among these four new potential mitochondrial 
regulators the gene number 9 (Zc3h10) was preferred primarily because its function is 
not yet annotated. This gene is zinc finger CCCH type containing 10 (Zc3h10), and it 
belongs to a nucleic acid binding protein family. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.3: Scatter plot. This graph correlates the dataset of the mtDNA quantification 
reported in fig. 9 and the dataset of the Oxygen consumption reported in fig. 10. 
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5.4	  Characterization	  of	  Zc3h10	  in	  myoblasts	  
After choosing our best candidate, we decided to characterize the mitochondrial 
function of Zc3h10 protein in C2C12 myoblasts. To evaluate the transfection 
efficiency we transfected the GFP and the fluorescence was detected by microscope 
before performing each single experiment.	  	  
5.4.1	  Evaluation	  of	  Zc3h10	  expression	  level	  C2C12	  myoblast	   either	   transfected	   with	   the	   empty	   vector	   (CTRL)	   or	   with	   the	  expression	   vector	   for	   Zc3h10	   were	   lysed	   and	   a	   western	   blot	   analysis	   was	  conducted	   to	   evaluate	   the	   endogenous	   expression	   levels	   of	   Zc3h10	   and	   the	  amount	   of	   its	   overexpression.	   As	   shown	   in	   Fig.	   5.4.1	   we	   were	   able	   to	   detect	  endogenous	   Zc3h10	   and	   an	   increase	   of	   two	   folds	   the	   expression	   level	   of	   the	  overexpressed	  protein. 
 
 
 
 
 
Figure 5.4.1: Western blot of the Zc3h10 protein. (A) Myoblasts transiently transfected with 
the empty vector (CTRL) and Zc3h10 were collected and the expression level of the Zc3h10 
protein was evaluated. (B) Quantification of the Zc3h10 expression level performed using 
Imagej. Statistical analysis was performed using t-test, **P<0.01, *vs CTRL. 
 
	  
5.4.2	  Evaluation	  of	  Tfam	  activation	  by	  Zc3h10	  
As we analyzed the Tfam promoter activity in HEK293 cell during the HT screening, 
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we decided to confirm the data in C2C12 myoblasts. We co-transfected the reporter 
system (Fig. 5.4.2.1 A), where the luciferase gene is under the control of the Tfam 
promoter, together with the cDNA encoding PGC-1α, as positive control, or the 
cDNA encoding Zc3h10. 24 hours after transfection, the promoter activity was 
evaluated. As shown in Fig. 5.4.2 C the overexpression of PGC-1α stimulated the 
Tfam promoter activity but also the overexpression of Zc3h10 produced the same 
effect. Therefore, we can conclude that also in C2C12 myoblasts Zc3h10 stimulated 
the Tfam transcription, even though at present the molecular mechanism is still 
unclear. 
Wu et al. demonstrated that PGC-1α trans-activates Tfam transcription by co-
activating the transcription factor NRF1[63]. In fact, they showed that when deleting 
the NRF1 binding site in the Tfam promoter, the PGC-1α was no longer able to 
induce the promoter activity. We used the same mutated Tfam reporter system (Tfam 
MUT, Fig. 5.4.2.1 B), deleted in the NRF1 binding site, to assess if the mechanism of 
action of Zc3h10 could be similar to that of PGC-1α. We co-transfected the mutated 
form of the reporter system with the empty vector (CTRL), the cDNA encoding PGC-
1α and the cDNA encoding Zc3h10 in myoblasts. As result, the overexpression of 
PGC-1α did not affect the promoter activity of the mutated reporter system, as 
expected. While the overexpression of the selected hit induced the promoter activity 
in both wild type and mutated reporter systems, suggesting a mechanism of action 
different from that of PGC-1α. It is worth to notice that, if the NRF-1 binding site is 
deleted (Tfam MUT), the activity of the promoter stimulated by the overexpression of 
Zc3h10 is lower than that showed when the wild type Tfam promoter  (Tfam WT) is 
transfected (Fig. 5.4.2.1 C). This suggests that Zc3h10 could promote the 
transactivation of the Tfam promoter through both the NRFs. 
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Figure 5.4.2.1:Tfam promoter activity. (A) The scheme of the wild type (WT) Tfam reporter 
system is shown. (B) The scheme reports the mutated (MUT) Tfam reporter system. (C) 
Myoblasts were transiently co-transfected with the empty vector (CTRL), PGC-1α cDNA 
and Zc3h10 cDNA and the wild type and mutated Tfam reporter systems. Twentyfour hours 
after transfection the luciferase activity was evaluated. Data are expressed as means ± sd, 
setting at 1 the luciferase activity measured in cells transfected with the empty vector 
(CTRL). Statistical analysis was performed using t-test,*P<0.05, **P<0.01, ***P<0.001;*vs 
CTRL WT, §vs CTRL MUT, #vs Zc3h10 WT. 
 
To confirm that the results obtained in Fig. 5.4.2.1 was not an aspecific effect 
mediated by the interaction of the PGC-1α or Zc3h10 with the backbone of the 
reporter system (pTK-LUC), we performed the same experiment also with the pTK-
LUC vector. Fig.5.4.2.2 showed that PGC-1α and Zc3h10 did not induce pTK-LUC 
transcriptional activity while these effects are seen when the reporter system contains 
the Tfam promoter as also previously observed.  
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Figure 5.4.2.2: pTK LUC and Tfam promoter activity. Myoblasts were transiently co-
transfected with the empty vector (CTRL), PGC-1α cDNA and Zc3h10 cDNA and the WT 
Tfam reporter system or the pTK LUC vector. 24 hours after transfection the promoter 
activity was evaluated. All data were expressed setting at 1 the luciferase activity measured in 
cells transfected with empty vector. Statistical analysis was performed using t-test, *P<0.05, 
**P<0.01, ***P<0.001;*vs CTRL pTK LUC, #vs CTRL Tfam LUC. 	  	  
5.4.3	  Evaluation	  of	  Oxygen	  Consumption	  Rate	  
We decided to deeply characterize the effects produced by overexpression of Zc3h10 
analyzing the oxygen consumption rate in uncoupling condition and in maximal 
respiration. The uncoupled respiration was evaluated adding oligomycin, an ATP 
synthase inhibitor, which, by blocking the ATP synthase proton channel, uncouples 
ATP phosphorylation from electron transport chain. In this condition, mitochondria 
do not produce ATP and the ATPse proton channel does not work, the only way the 
protons have to enter into the mitochondrial matrix is through the proton leak 
mediated by UCPs yielding heat (Fig. 5.4.3.1 B). Consequently, the ETC slows down 
and the cell consumes less oxygen. On the other hand, the maximal respiration was 
reached adding the carbonyl cyanide m-chlorophenylhydrazone (CCCP), a lipophilic 
compound that transports the protons through the inner mitochondrial membrane, 
dissipating the electrochemical gradient and maximizing the mitochondrial respiration 
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(Fig. 5.4.3.1 C). The CCCP-stimulated oxygen consumption therefore reflects the 
number of mitochondria and/or the electron transport activity.  
 
 
 
 
 
 
 
 
 
Figure 5.4.3.1: Model illustrating the (A) Basal respiration, (B) Uncoupled respiration and (C) 
maximal respiration. The figure is adapted from Wu Z. et al., Cell, 1999, Vol 98, 115-
124[63]. 
 
C2C12 myoblasts were transiently transfected with the different vectors (empty 
vector, PGC-1α and Zc3h10 cDNAs), and analyzed 60 hours after transfection. The 
basal, uncoupled and maximal respiration was evaluated in the conditions 
summarized in. Fig.5.4.3.1 shows that the addition of oligomycin decreased the 
oxygen consumption as expected, while the addition of CCCP led to a maximal level 
of respiration in all myoblasts transfected with the different cDNAs. As previously 
shown (Fig. 5.4.3.2), the overexpression of both PGC-1α and Zc3h10 increased the 
basal oxygen consumption rate. In addition, we found that the overexpression of 
PGC-1α increased the uncoupled respiration by 2 folds compared to cells transfected 
with the empty vector, confirming data already present in literature [63]. In addition, 
also the overexpression of our selected hit had the same effect (a 2 folds increase), 
indicating that Zc3h10 stimulates the uncoupling of mitochondria in these cells. 
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Considering the maximal respiration, the overexpression of our positive control 
induced the CCCP-stimulated oxygen consumption by around 2 folds [63] while 
Zc3h10 by 1.5 folds compared to cells transfected with the empty vector. This result 
indicated that these cells had a higher content and/or electron transport activity of 
mitochondria. 
 
 
 
 
 
 
 
 
 
Figure 5.4.3.2: Oxygen Consumption. C2C12 myobla ts transfected with the empty vector 
(CTRL), with PGC-1α and Zc3h10 cDNAs. At 60 hours after transfection the cells were 
detached from the plates and transf rred to a chamber for measurement of oxygen 
consumption. The concentration of oligomycin was 1.25 µM and the concentration of the 
CCCP was 3.75µM. All data were normalized by the protein content. Statistical analysis was 
performed using t-test,*P<0.05, **P<0.01, ***P<0.001;*vs CTRL Basal,#vs PGC-1α Basal 
§vs Zc3h10 Basal, *vs CTRL Oligo, *vs CTRL CCCP. 	  	  
5.4.4	  Evaluation	  of	  OXPHOS	  proteins’	  expression	  levels	  
To corroborate the underlying cause of this increased function, we decided to evaluate 
the expression of the OXPHOS proteins by western blot analyses. As shown in Fig. 
5.4.4, the overexpression of Zc3h10 increased the protein level of all the subunits of 
the OXPHOS complexes to the same extent of the positive control PGC-1α, thus	  indicating	   that	   the	   increased	  mitochondrial	   function	   is	   associated	   with	   higher	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expression	  of	  the	  OXPHOS	  genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.4: Western blot of the OXPHOS proteins. (A) Myoblasts transiently transfected 
with the empty vector (CTRL), PGC-1α and Zc3h10 cDNAswere collected and the 
expression level of the OXPHOS proteins was evaluated. (B) Quantification of the expression 
levels of the indicated OXPHOS complexes was performed using Imagej. Statistical analysis 
was performed using One way ANOVA followed by Dunnett’s multiple comparison 
test,*P<0.05, **P<0.01, ***P<0.001;  *vs CTRL. 	  
5.4.5	  Evaluation	  of	  ATP	  Production	  
ATP production is coupled	   to	   mitochondrial	   respiration, therefore, an increased 
ATP production should be observed in conditions of induced mitochondrial activity. 
Consequently, we evaluated the total amount of ATP (both mitochondrial and 
cytosolic) in myoblasts overexpressing our selected hit and the positive control. The 
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overexpression of both PGC-1α and Zc3h10 increased the total content of ATP (Fig. 
5.4.5, sum of the white and black bars). We decided to evaluate if the observed  
increase was due to the cytosolic or to the mitochondrial fraction. To evaluate the 
cytosolic ATP, we treated cells with oligomycin (an ATP synthase inhibitor) and we 
observed no difference in ATP levels (Fig. 5.4.5, white bars). The mitochondrial ATP 
amount was evaluated as the difference between the total level and the cytosolic 
fraction. We found increased mitochondrial ATP content both in myoblasts 
overexpressing PGC-1α and Zc3h10 (Fig.5.4.5, black bars). Once again, these results 
confirm that the overexpression of both the positive control (PGC-1α) and Zc3h10 
stimulate the mitochondrial function.  
 
 
 
 
 
 
Figure 5.4.5: ATP production. C2C12 myoblasts were transfected with the empty vector 
(CTRL), with PGC-1α and Zc3h10 cDNAs. At 60 hours after transfection the amount of ATP 
was evaluated using the ATPlite kit (Perkin Elmer). The concentration of cytosolic ATP was 
measured treating cells with 10 µM oligomycin for 24 hours. The amount of mitochondrial 
ATP was calculated as the difference between the total amount of ATP and the cytosolic 
fraction. Statistical analysis was performed using One way ANOVA followed by Dunnett’s 
multiple comparison test,*P<0.05, **P<0.01, ***P<0.001;  *vs CTRL total ATP amount; §vs 
CTRL mitochondrial ATP amount. 
 
	  
5.4.6	  Evaluation	  of	  Reactive	  Oxygen	  Species	  Production	  
Mitochondrial metabolism is responsible for the majority of the reactive oxygen 
species (ROS) production in the cell [182]. The formation of ROS occurs when 
unpaired electrons escape the electron transport chain and react with molecular 
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oxygen, generating superoxide [183]. Superoxide can react with DNA, proteins, lipids 
and plays an important role in many physiological and pathophysiological conditions. 
The maintenance of low ROS levels is critical to normal cell functions, therefore, an 
increase in mitochondrial activity carry an inherent risk of increasing ROS levels. 
Consequently, we measured this parameter by a fluorescence-based assay using the 
2',7'-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) probe. The cell-permeant 
H2DCFDA is a chemically reduced form of fluorescein used as an indicator of 
reactive oxygen species in cells. Upon cleavage of the acetate groups by intracellular 
esterases and oxidation, the non fluorescent H2DCFDA is converted to the highly 
fluorescent 2',7'-dichlorofluorescein (DCF). Myoblasts, 60 hours after transfection 
with the empty vector (CTRL), or the plasmid expressing PGC-1α and Zc3h10 were 
incubated with the probe. As positive control, we used myoblasts transfected with the 
empty vector and then treated with H2O2, a powerful type of ROS.  
 
 
 
 
 
Fig.5.4.6: Reactive Oxygen Species measurement. C2C12 myoblasts were transfected with 
the empty vector (CTRL), with PGC-1α and ZC3H10 cDNAs. At 60 hours after transfection 
the cells were treated with CM-H2DCFDA 5µM. As positive control we used myoblasts 
transfected with the empty vector and treated with 25 µM H2O2 for 30 minutes. All data were 
normalized by the protein content and were expressed setting at 1 the signal measured in cells 
transfected with empty vector. Statistical analysis was performed using One way ANOVA 
followed by Dunnett’s multiple comparison test,*P<0.05, **P<0.01, ***P<0.001;  *vs 
CTRL. 
 	  
As shown in Fig. 5.4.6 the overexpression of PGC-1α did not enhance the ROS 
production, because as reported in literature PGC-1α is able to counterbalance the 
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ROS production inducing the expression of two enzymes (catalase and superoxide 
dismutase 2) involved in the catabolism of ROS [184]. The overexpression of Zc3h10 
did not increase the ROS level, as well. Despite the increased oxygen consumption 
rate measured in cells overexpressing either PGC-1α or Zc3h10, we did not observed 
abnormal level of ROS. This could be due to the activation/induction of antioxidant 
enzymes, as reported in systems overexpressing PGC-1α. 	  
5.4.7	  Measurement	  of	  the	  mitochondrial	  membrane	  potential	  
Apoptosis is a normal process of organismal development. Induction of this process 
can arise from a variety of stimuli. The intrinsic pathway, also referred to as 
mitochondrial-mediated apoptosis, is initiated via intracellular signals, such as DNA 
damage and oxidative stress. Mitochondria own a mitochondrial transition pore that 
when activated opens a channel in the mitochondrial inner membrane, short circuits 
proton electrochemical gradient, and initiates programmed cell death (apoptosis). One 
of the early markers of the mitochondrial-mediated apoptosis is a decrease in the 
mitochondrial membrane potential. Indeed, we decided to measure this parameter 
using the JC-1 probe. JC-1 is a cationic dye that exhibits potential-dependent 
accumulation in mitochondria, indicated by a fluorescence emission shift from green 
(~525 nm) to red (~590 nm). Consequently, mitochondrial depolarization is indicated 
by a decrease in the red/green fluorescence intensity ratio. The potential-sensitive 
color shift is due to concentration-dependent formation of red fluorescent J-
aggregates. At 60 hours after transfection the myoblasts transfected with the empty 
vector (CTRL), or the vectors encoding PGC-1α and Zc3h10 were treated with the 
JC-1 probe. As positive control, we use myoblasts transfected with the empty vector 
and then treated with CCCP, which	   causes	   quick	   mitochondrial	   membrane	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depolarization. Fig. 5.4.7 shows that neither the overexpression of PGC-1α nor the 
overexpression of Zc3h10 affected the membrane potential. 
 
 
 
 
 
 
 
Figure 5.4.7: Inner mitochondrial membrane potential measurement. C2C12 myoblasts were 
transfected with the empty vector (CTRL), with PGC-1α and ZC3H10 cDNAs. At 60 hours 
after transfection the cells were treated with 3µM JC-1 probe. As positive control we used 
myoblasts transfected with the empty vector and treated with 10 µM CCCP for 30 minutes. 
All data were normalized by the protein amount and were expressed setting at 1 the 
fluorescence ratio measured in cells transfected with the empty vector. Statistical analysis was 
performed using One way ANOVA followed by Dunnett’s multiple comparison test,*P<0.05, 
**P<0.01, ***P<0.001; *vs CTRL. 
 	  
5.4.8	  Analysis	  of	  the	  Zc3h10	  promoter	  
Since the function of Zc3h10 is completely unknown till now, no data are present in 
the literature describing its mechanisms of action or the way it is activated or 
regulated. Analyzing the Zc3h10 promoter (907 bases) on TFSearch 
(http://www.cbrc.jp) we found a putative highly conserved binding site for NRF-2 on 
its sequence (Fig. 5.4.8.1).  
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Figure 5.4.8.2: NRF-2 binding site. We searched the sequence of the Zc3h10 promoter 
purchased from SwitchGear into the Genome Browser (http://genome-euro.ucsc.edu). We 
found that the Zc3h10 is on the chromosome 12. Underlined in blue there are the NRF-2 
putative binding site, that is highly conserved between different species. 
 
We decided to investigate also if some other very well known mitochondrial 
regulators could in some way also regulate Zc3h10. We co-transfected the reporter 
system where luciferase was under the Zc3h10 promoter (Zc3h10-LUC), and the 
empty vector as control or the cDNAs of NRF2, PGC-1α, SIRT1, NRF1 and Zc3h10. 
24 hours after the transfection, the promoter activity was evaluated.  
 
 
 
 
 
 
Figure 5.4.8: Zc3h10 promoter activity. Myoblasts were transiently co-transfected with the 
Zc3h10 reporter system and the empty vector (CTRL), NRF2, PGC-1α, SIRT1, NRF1 or 
Zc3h10 cDNAs. 24 hours after transfection the promoter activity was evaluated. Statistical 
analysis was performed using One way ANOVA followed by Dunnett’s multiple comparison 
test,*P<0.05, **P<0.01, ***P<0.001; *vs CTRL. 
As shown in Fig. 5.4.8.2, NRF2 induced the Zc3h10 promoter activity about 3 folds, 
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PGC-1α and SIRT1 increased the promoter activity of 2 folds, Zc3h10 about 1.8 folds 
suggesting a possible auto-regulation and surprisingly NRF1 seemed to inhibit the 
activity. These data are very promising, but more experiments should be performed in 
order to better understand these relationships between Zc3h10 activation and other 
mitochondrial regulators. 	  
5.4.9	  Zc3h10	  expression	  levels	  in	  different	  mice	  organs	  
Since Zc3h10 characterization completely lacks, we decided to measure the 
expression level of this gene by qRT-PCR in different organs of C57BL6/J mice. We 
chose the organs that are rich in mitochondria mainly correlated in metabolism.  
 
 
 
 
 
 
Figure 5.4.9: Zc3h10 gene expression in different tissues. Four 10 weeks old C57 Black 6 
mice were sacrificed and the gene expression was measured by qRT-PCR.  
 
 
As shown in Fig. 5.4.9, the main tissues in which the Zc3h10 is expressed are the 
liver, the soleus and the central nervous system.  
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6.	  Discussion:	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Mitochondria are the powerhouse of the cells, since they produce the energy (ATP) 
necessary for all cellular functions. Apart from this main function, mitochondria are 
involved in many other metabolic processes like the oxidative catabolism of amino 
acids, ketogenesis, the urea cycle, the generation of ROS, the control of cytoplasmic 
calcium and the synthesis of all cellular Fe/S clusters. Consequently,	  the	  molecular	  mechanisms	   underlying	   their	   regulation	   and	   functions	   represent	   a	   highly	  relevant	  aspect	  of	  cell	  homeostasis.  
Mitochondria are organelles possessing their own genome, which	  codes	  for	  some	  of	  the	  subunits	  of	  the	  ETC/OXPHOS	  complexes. Mitochondrial activities are mediated 
by thousands of mitochondrial-specific proteins encoded by both the nuclear (nDNA) 
and the mitochondrial (mtDNA) genome [2, 3]. Hence, the nuclear-mitochondrial 
crosstalk is at the basis of energy metabolism thus	   playing	   a	   key	   role	   in	   many	  cellular	   functions. The mtDNA replication and transcription are regulated by a 
nuclear-encoded transcription factor, called Tfam. In turn, the Tfam transcription is 
regulated by other nuclear-encoded factors. For example, PGC-1α, one of the best 
known among these factors, transactivates Tfam by the coactivation of another 
nuclear encoded transcription factor such as NRF-1. In fact, as reported in literature 
the overexpression of PGC-1α increases the basal respiration, a functional parameter 
to evaluate the mitochondria activity. PGC-1α overexpression increases also the 
mtDNA content, suggesting an increased mitochondrial biogenesis and also the 
expression level of the ETC proteins [63]. Many aspects at the basis of mitochondrial 
biology have	  not	  been	  fully	  deciphered, like the mechanisms controlling i) mtDNA 
replication and transcription, ii) the dynamics of mitochondrial fusion and fission and 
iii) the nuclear-mitochondrial crosstalk.  
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As mitochondria are so important for whole body metabolism, mitochondrial 
dysfunction is associated to many diseases such as diabetes, neurodegenerative 
disorders and aging. Nevertheless, the contribution of mitochondria to the pathogenic 
mechanisms underlying these pathologies is not completely characterized. Therefore, 
the aim of this project was to identify new mitochondrial regulators in order to gain 
knowledge in mitochondrial biology and to get new insights on the role of 
mitochondria in pathophysiology.  
One possible approach for the screening of new regulators could be the yeast two-
hybrid system, the same used by Puigserver et al. in 1998 for the identification of 
PGC-1α [115]. They cloned murine PPARγ in-frame into the GAL4 DNA-binding 
domain (BD) plasmid pAS2. In addition, a HIB 1B (murine brown adipocyte cell line) 
cDNA expression library was constructed in the GAL4 activation domain (AD) 
plasmid pACT II. This screening approach is based on the fact that if the PPARγ and 
one library-encoded protein interact (i.e., bind), then the AD and BD are indirectly 
connected, bringing the AD in proximity to the transcription start site and 
transcription GAL4 can occur. If the two proteins do not interact, there is no 
transcription of the reporter gene. In this way, a successful interaction between the 
fused proteins is linked to a change in the cell phenotype. Another possible screening 
methods could be the same used by Puigserver et al. to discover if PGC-1α 
specifically interacts with members of the nuclear hormone receptor superfamily 
[115]. They used GST-purified fusion proteins of PGC-1α immobilized on 
glutathione beads and incubated them with PPARγ and other nuclear receptors. The 
beads were then washed and the sample was processed by electrophoresis. After 
fixation and enhancement the radiolabeled proteins were visualized by 
autoradiography. The two screening methods just described, allow isolating proteins 
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that interact physically, but they are very time consuming and complicated. The 
sequencing of the human genome in 2003 holds benefits for many fields, from 
molecular medicine to human evolution. In fact, the Human Genome Project, through 
its sequencing of the DNA, helped to understand diseases but also allowed the 
commercial development of genomics research related to DNA based products, like 
cDNA libraries. These libraries, now commercially available, accounts for all the 
genes with and without an annotated function present in many organisms, like Homo 
sapiens, Mus musculus, Drosophila melanogaster and Escherichia coli. These libraries 
drastically affected all the screening approaches allowing high-tech type of 
experiments and high throughput screenings.  
One of the major challenging nowadays is the identification of the molecular 
functions and the biological processes in which the proteins encoded by the genome 
are involved. This project exactly aims at the same objective, even if just related to 
mitochondria. In fact, we want to identify new mitochondrial regulators whose 
mitochondrial function was not yet reported. We found three proteins (nr. 10, 13, 19) 
to be active in mitochondria that are also involved in other pathways. More 
surprisingly, we discovered the mitochondrial involvement of Zc3h10, a protein 
whose function where previously completely uncharacterized.  
In order to accomplish the aim of finding new mitochondrial factors, we should select 
a functional assay that could be applied to such a large number of potential regulators, 
the whole genome. In addition the approach should be relatively fast, allowing an 
easy deconvolution of results, easy to perform in robotic fashion and robust (i.e., few 
false negatives/positives). The most suitable approach that fulfills all these 
requirements is a HTS. The one we set up was also reproducible, as the positive 
clones identified counted also some very well known mitochondrial regulators as 
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CREB. We set up a genome-wide HTS, where we arrayed onto 384 wells plate a 
single cDNA spotted per well (in total 27000 genes were screened); individual 
cDNAs were co-transfected with a luciferase reporter to measure the activity of Tfam. 
The HEK 293 was used as cell line. There are many examples in literature of different 
HTS; nowadays they are widely used for screenings. Nevertheless, they have some 
limitations. It is not atypical, particularly for initial genome-wide screens in an 
organism, for the primary screen to be the only experimental data in the study. Apart 
from the value of the list of genes that are implicated in the process of interest, several 
systems-wide conclusions can be drawn by looking at the data as a whole rather than 
focusing on individual genes [185]. In addition, we were aware of the fact that the 
activation of the Tfam promoter does not automatically imply the discovery of a 
mitochondrial regulator. Hence, we chose a further assay to get an idea of the effects 
of these mitochondrial candidate genes. Considering the large number of cDNAs, we 
used fluorescent probes with a reported mitochondrial selectivity, to evaluate the 
density (Mitotracker® Green) and the oxidative capacity (Mitotracker® CM-H2X-
ROS). We were aware that the use of these probes is not a method certified and 
widely accepted, but allowed us to narrow down the number of the positive 
candidates to 131. To complete the screenings, we got some insights about the 131 
positive candidates identified, using bioinformatics tools. We classified the genes for 
their molecular function and biological process, for their expression level in murine 
skeletal muscle and C2C12 and assessing they were not yet related with mitochondria. 
In this project we decided to study a limited number of candidate genes, but sufficient 
to guarantee to find out a new mitochondrial regulator in a reasonable time. Our 
choice was to further characterize 22 genes in C2C12 cell lines; 3 involved in the 
catalytic activity, 4 in signal transduction, 11 in transcription processes, 4 structural 
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proteins and 1 whose function is not yet annotated. The most abundant class is 
composed of proteins involved in transcriptional processes, as transcription factors 
have e regulatory function by definition. Additionally, we chose a gene with a not 
annotated function, as its identification could be a major finding, too. The use of 
HEK293 for high throughput screening is very common, in fact these cell are easy to 
manage and to transfect and in addition, their physiology and metabolism are very 
well characterized. Nevertheless, the use of skeletal muscle cells is one of the most 
common used for the study of other mitochondrial regulators, as shown in literature. 
Skeletal muscle is one of the tissues most highly dependent on mitochondrial 
function, as shown by the severe impacts of mitochondrial diseases on muscle 
performance in patients [180]. In addition, mitochondrial dysregulation was 
demonstrated in muscle of patients suffering from type II diabetes [134]. For this 
reason we decided to validate the 22 candidates in C2C12, a murine skeletal muscle 
cell line. In principle we expect that a regulator should affect the mitochondrial 
biogenesis and/or activity, especially the oxidative activity. In fact, PGC-1α (our 
positive control) acts on both aspects. One of the most reliable methods for assessing 
the biogenesis is the measurement of mtDNA. It is a direct measurement, based on the 
extraction of the DNA, so it has more advantages than the use of the fluorescent 
probes utilized in the previous screening. Surely, mtDNA measurement is a quite long 
and complicated procedure, not suitable for high numbers of samples. Regarding the 
oxidative activity, the biochemical method of excellence is the measure of the 
respiration. We evaluated the oxygen consumption with a Clark electrode, which is a 
very complicated and long analysis. We analyzed the respiration of the whole cells. 
We did not extract mitochondria, as it is a very invasive method that can affect the 
analysis. Using this approach for hundreds of samples is a very time consuming and 
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biases-rich methodology. As reported in our results, not always an increased 
mitochondrial biogenesis reflects an induced mitochondrial activity. This means that 
an increased mitochondrial biogenesis is necessary but not sufficient to ensure an 
increased mitochondrial function. We measured the mtDNA content as hallmark of 
mitochondrial biogenesis, but it could be possible that an increased number of copies 
of mtDNA do not correlate with an increased in the number of mitochondria; the 
mtDNA is just more replicated. On the other hand, the increased copies of mtDNA 
correlate with an increased mitochondrial biogenesis, but the mtDNA is just neither 
transcribed nor translated. As the mitochondrial genes transcription is under the 
strictly control of the nucleus [181], a possible explanation may be due to the nucleus 
that blocks the mtDNA transcription because the cell at that moment does not require 
an increased mitochondrial function or some other unknown mechanisms controlling 
the nucleus-mitochondrial crosstalk intervenes. We must not forget that the mtDNA 
encodes only 13 proteins that are not enough to exploit all the mitochondrial 
activities; so the transcription and translation of the mitochondrial genome must be 
coordinated to the expression of nuclear-encoded mitochondrial proteins. For these 
reasons, we considered as positive mitochondrial regulators only those candidates 
whose overexpression stimulated both the mitochondrial biogenesis and function as 
performed by our positive control PGC-1α. Applying these assays, we identified four 
genes (nr. 9, 10, 13 and 19) that if overexpressed in C2C12 showed a mitochondrial 
function better than or equal to our positive control PGC-1α.  
We decided to prioritize the characterization of the candidate nr. 9, zinc finger CCCH 
type containing 10 (Zc3h10), because it was a protein with a not yet annotated 
function. Zc3h10 is very well conserved in all the Eutheria organisms (source 
http://string90.embl.de) but in literature, were reported only modest amount of articles 
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that mention this protein. One suggests a possible tumor suppressor function of 
Zc3h10 as it inhibits anchorage independent growth in soft agar [186], but it is a HTS 
that do not provide any information about the mechanism. In one other article, a yeast 
two-hybrid system screening shows that Zc3h10 binds the ataxin-1 (ATXN-1)[187]. 
The normal function of ATXN-1 is not yet known, but the mutated form of the 
protein is associated to the Spinocerebellar ataxia type 1, a neurodegenerative 
disorder [188]. Hence, the major finding of this project was to assess a mitochondrial 
function to Zc3h10. As shown in our detailed biochemical characterization, Zc3h10 
overexpression increased the expression profile of OXPHOS proteins, increased the 
content and/or electron transport activity of mitochondria (measured by uncoupling 
and maximal respiration) and increased the mitochondrial ATP production. In 
addition, the Zc3h10 overexpression was not associated with toxic effects related to 
the activity of mitochondrial ROS production and induction of apoptosis. It is worth 
noting that, although ubiquitously expressed, Zc3h10 mRNA levels were high in 
metabolically active tissues like liver, soleus and brown adipose tissue. These tissues 
are rich in mitochondria as one of their functions is fuel oxidation, thus this data 
confirm the mitochondrial function of Zc3h10.  
According to our bioinformatics classification, Zc3h10 is a nucleic acid binding 
protein; even if we do not know if it binds DNA or RNA. This classification is 
confirmed by some other members of Zc3 protein family; for example Zc3h12a is an 
essential RNase that prevents immune disorders by directly controlling the stability of 
a set of inflammatory genes [189]. As a consequence, we could hypothesize that 
Zc3h10 could act as a transcription factor (like NRF-1/2) or as a factor that regulates 
in some way the expression of mitochondrial genes (like PGC-1α), but ad hoc 
experiments should be performed to answer this question. In these regards, we 
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discovered that Zc3h10 explicates its mitochondrial function activating the promoter 
of Tfam, as shown in two different cell lines (HEK293 and C2C12) as our positive 
control PGC-1α. The portion of Tfam used for the analysis contained the binding sites 
for SP1, NRF-1 and NRF-2. From literature we know that PGC-1α transactivates 
Tfam by coactivating NRF-1 [63]. Regarding Zc3h10 we found that, mutation of the 
NRF-1 binding site slightly reduced but did not abolished the Tfam activation by our 
best candidate, suggesting that the rest of the promoter, including the NRF-2 and SP-1 
binding sites, could mediate the effect of Zc3h10. This mode of action is different 
from that one of PGC-1α, but further experiments should be performed to understand 
the mechanism of action of Zc3h10.  Complex	   transcriptional	   circuitries	   have	   been	   demonstrated	   to	   regulate	  mitochondrial	   DNA	   replication	   and	   transcription.	   For	   example,	   most	   of	   the	  mitochondrial-­‐	   or	   nuclear-­‐encoded	   OXPHOS	   subunits	   have	   a	   binding	   site	   for	  NRF-­‐1	  or	  NRF-­‐2	  on	  their	  promoter;	  SIRT-­‐1	   is	  a	  histone	  deacetylase	   that	  affects	  
PGC-1α	  expression	  [190].	  With	  this	  in	  mind	  we	  analyzed	  the	  sequence	  of	  Zc3h10	  promoter	   in	  silico	   and	  we	   found	   that	   it	   could	  have	  a	  NRF-­‐2	  binding	   site	   that	   is	  highly	  conserved	  between	  organisms.	  Screening	  different	  master	  mitochondrial	  regulators	   for	   their	   ability	   to	   activate	   the	   Zc3h10	   promoter	   activity,	  we	   found	  that	   NRF-­‐2,	   PGC-­‐1α and SIRT-1 positively regulates its transcription, while 
surprisingly NRF-1 seems to have an inhibitory effect. In addition, Zc3h10 seems to 
have a kind of auto activation, but further experiment should be performed to 
characterize and explain all these effects and to describe how Zc3h10 is regulated.  
As	  well	  established	  in	  literature,	  a	  mitochondrial	  dysfunction	  is	  associated	  to	  many	  
diseases;	   one	   of	   the	   most	   studied	   is	   the	   T2D.	   In	   literature,	   it	   is	   known	   that	   the	  
skeletal	   muscle	   mitochondria	   of	   T2D	   patients	   show	   a	   reduction	   in	   their	   activity	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that	  reflects	  a	  decrease	  expression	  profile	  of	  many	  mitochondrial	  genes	  [51,	  157].	  
For	   example,	   the	   expression	   profile	   of	   PGC-­‐1α	   is	   decreased	   by	   nearly	   50%	   in	  muscle	   from	   individual	   with	   diabetes	   [157].	   Preliminary	   results	   performed	   in	  our	   laboratory,	   showed	   that	   the	   expression	   profile	   of	   Zc3h10,	   as	  well	   as other 
mitochondrial-related factors like PGC-1α, Tfam and mtCOXII, is reduced in skeletal 
muscle of mice with high fat diet-induced diabetes (data not shown). Even if we don’t 
know the molecular mechanisms causing this effect and this result should be 
supported by other experiments, we can conclude that the expression profile of 
Zc3h10 follows the same trend of reduction observed in other mitochondrial factors in 
the skeletal muscle of a mitochondrial dysfunction animal model. This once again 
sustains the evidence that Zc3h10 has a mitochondrial function. 
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7.	  Highlights:	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• Integrating different approaches like the high throughput screening, staining 
assays, bioinformatics tools and functional/biochemical approaches, we were able 
starting from 27000 cDNAs to identify one gene that is a mitochondrial 
regulators.   
• We assessed the mitochondrial function of Zc3h10. In fact, we demonstrated that 
its overexpression affected the Tfam promoter activity, increased the mtDNA 
content (a hallmark of mitochondrial biogenesis) and induced the oxygen 
consumption rate, the expression of the OXPHOS proteins and the mitochondrial 
ATP levels (a hallmark of mitochondrial function), without affecting the ROS 
production or apoptosis. 
• We discovered one of the functions of Zc3h10, whose activity was previously 
completely unknown. Further experiments should be performed in order to 
understand its mechanism of action, but we were able to frame it in a particular 
biological context, the mitochondrial regulation. 
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